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ABSTRACT 
Asthma and other allergy related diseases are the most common chronic diseases in 
childhood, and have become a major public health concern. The rapid increase in the 
occurrence of these diseases, especially in high-income countries, has led to the study of the 
role of various environmental and lifestyle factors. The overall aim of this thesis was to 
evaluate the association between indoor environmental factors and the development of 
allergic diseases in childhood and adolescence, and more specifically, to study the association 
between tobacco smoke exposure during pre- or postnatal life as well as exposure to indoor 
mold or dampness and allergic diseases from birth to age 16 years. We used data from the 
Swedish prospective birth cohort BAMSE (N = 4089) and in study III data from BAMSE 
combined with four other European birth cohorts (N = 10860). 
We found that exposure to maternal smoking during pregnancy was associated with 
asthma up to adolescence, especially early-transient asthma. Additionally, exposure to high 
doses of maternal smoking during pregnancy (≥10 cigarettes/day) was associated with 
persistent asthma as well as persistent rhinoconjunctivitis up to age 16 years. Based on 
spirometry, exposure to maternal smoking during pregnancy was also associated with lower 
FEV1/FVC ratios at age 16 years. Additionally, indices from impulse oscillometry indicated 
increased peripheral airway resistance at age 16 years among subjects exposed to maternal 
smoking during pregnancy.  
Exposure to secondhand smoke (SHS) during infancy was associated with overall 
increased risks of asthma, rhinitis, and eczema up to adolescence. However, we found 
suggestive evidence that the association between SHS during infancy and asthma was likely 
driven by exposure in utero. Our findings indicate that exposure to SHS during infancy, 
without prior exposure to maternal smoking during pregnancy, was associated with food 
allergen sensitization up to age 16 years. Furthermore, exposure to SHS during infancy was 
associated with increased risks of rhinitis without concomitant sensitization and eczema with 
concomitant sensitization. SHS exposure during other periods of childhood was not 
associated with the onset of asthma or rhinoconjunctivitis in adolescence.  
Compared with non-smokers, participants who smoked daily or occasionally tended to 
have reduced FEV1/FVC ratios at age 16 years, even after controlling for maternal smoking 
during pregnancy. Using indices from impulse oscillometry (IOS) we found increased 
peripheral airway resistance among adolescent smokers. These findings were corroborated 
when we used saliva cotinine concentrations to discriminate smokers from non-smokers.   
Exposure to indicators of mold or dampness during infancy were associated with 
increased risk of asthma up to age 16 years, as well as an increased risk of persistent asthma. 
We also found suggestive evidence of an association between reported mold odor or visible 
mold during infancy and rhinitis up to age 16 years. No association between exposure to 
indicators of mold or dampness and IgE sensitization was observed.  
In conclusion, findings from the studies included in this thesis suggest that exposure to 
maternal smoking during pregnancy is associated with asthma and measures of airway 
obstruction, such as reduced FEV1/FVC ratios, up to adolescence. Exposure to SHS during 
infancy seems to be associated with food allergen sensitization and rhinitis up to age 16 
years. Adolescent smoking is associated with reduced FEV1/FVC ratios and increased 
peripheral airway resistance at age 16 years. Exposure to indicators of mold or dampness 
during infancy may be associated with an increased risk of asthma, and more specifically 
with persistent asthma up to age 16 years.  
The results from this thesis can be used to help inform public health policy as well as 
clinicians to motivate their patients to abstain from smoking. Indoor mold and dampness is a 
modifiable risk factor related to the onset and persistence of asthma in children and 
adolescence, and further research should focus on identifying the causal agents.    
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1 BACKGROUND 
1.1 ALLERGIC DISEASES 
1.1.1 Why study allergic diseases? 
In high and middle income countries allergic diseases such as asthma, rhinitis, and eczema 
are common. There has been an epidemic increase in allergic diseases which has led to 
research efforts aiming at assessing which lifestyle and environmental factors may be 
responsible for this increase.
1 2
 The global prevalence of asthma varies, and in Sweden the 
prevalence of asthma is 5-10%, while in North America, Australia, and the UK it exceeds 
>10%, and Asia has the lowest prevalence at <3%.
2-5
 Aspects of a “westernized” lifestyle, 
such as diet, increased cleanliness, widespread antibiotic use, indoor and outdoor air 
pollution, gas cooking, obesity, tobacco smoke exposure, and dampness-related exposures, 
have stimulated extensive research to identify factors which may be responsible. It is 
important for research to identify modifiable risk factors that lead to these diseases, as they 
not only have substantial impact on the individuals but also on society.
6 7
 Allergic diseases in 
general contribute to vast spending by governments and individuals to treat these chronic 
diseases. Additionally, lost productivity and sick days taken contribute to costs related to 
these diseases. Quality of life and general well-being are also reduced among individuals 
suffering from allergic diseases.
7-10
 
Individuals living in industrialized countries spend the majority of their time indoors, roughly 
80-90%.
11
 Therefore, the indoor environment plays a pivotal role in health and well-being. 
With increased focus being placed on energy efficient practices and rising energy costs, better 
insulated homes can lead to greater concentrations of indoor allergens and pollutants.
12
 
Indoor risk factors such as exposure to environmental microorganisms, gas cooking, dust 
mites, building characteristics, tobacco smoke exposure, indoor mold or dampness, are 
suggested to influence the development of allergic diseases in children.
12-17
 Tobacco smoke 
exposure as well as indoor mold or dampness constitute the focus of this thesis.  
1.1.2 Allergic diseases and the sensitization process 
Allergies are an abnormal adaptive immune response and are the most common disorders of 
the immune system affecting  around 10-20% of the global population.
18
 Immediate 
hypersensitivity, also known as type I hypersensitivity, is a reaction to often innocuous 
antigens (e.g. proteins) and is characterized by the production of allergen-specific 
immunoglobulin E (IgE).
18
  
The sensitization process begins when an individual is exposed to an antigen (allergen) for 
the first time. The uptake occurs at a mucosal site (in the airway, gut, or skin) where the 
allergen is taken up by antigen-presenting cells (dendritic cells) and leads to activation of 
naïve CD4+ cells.
19 20
 The naïve T cell is induced by cytokine interleukin 4 (IL4) to 
proliferate into a T2 helper cell (Th2). Subsequently, Th2 cells produce IL4 and IL13 that in 
turn simulate B cells to produce allergen-specific IgE antibodies, which bind to the surface of 
 2 
mast cells and basophils, priming them for future exposure.
18 21
 The individual is now 
considered to be “sensitized”. Subsequent exposure to the allergen will be recognized by the 
IgE-antibodies coating the mast cells and basophils, which will induce the activation of these 
cells and the allergic cascade begins, stimulating the release of inflammatory mediators and 
histamine which causes the characteristic allergic reaction (i.e. runny nose, sneezing, and 
itchy/watery eyes).  
1.1.3 Asthma 
Asthma is a chronic inflammatory disease characterized by airway inflammation and 
hyperreactivity. Asthma often presents as wheezing, shortness of breath, and coughing. 
Chronic airway inflammation often leads to alterations in the airway epithelium including 
increased production of smooth muscle cells and mucus secretion. Asthma is a complex 
disease with many forms and phenotypes, and it is likely that each has slightly different 
etiology and mechanisms.
22
 There is no “gold standard” for diagnosing asthma, which is 
based on a combination of patient history, symptoms, lung function tests, or airway 
provocation tests (e.g. methacholine challenge). In children under five years asthma may be 
challenging to diagnose, and can be misinterpreted with other conditions, such as respiratory 
infections that provoke wheezing. 
1.1.4 Rhinitis and rhinoconjunctivitis 
Rhinitis is common during childhood and adolescence, and is defined as inflammation of the 
nasal epithelium and characterized by nasal symptoms such as rhinorrhea, blocked and itchy 
nose, or sneezing.
23
 Multiple forms of rhinitis exist and they often overlap. The most 
common is allergic rhinitis, which is driven by IgE sensitization. Rhinoconjunctivitis, is 
similar to rhinitis, and is also characterized by one or more of the following symptoms – nasal 
congestion, rhinorrhea, sneezing, and red, itchy eyes (conjunctivitis).
24
  
1.1.5 Eczema 
Eczema, or atopic dermatitis, is a relapsing chronic inflammatory skin disorder which 
presents as pruritic rash and dry skin. There are no definitive diagnostic criteria, and 
diagnosis is based on patient history, recognition of symptoms, and clinical features. The 
Williams criteria are the most commonly used and validated criteria in diagnosing eczema.
25 
26
  
1.1.6 IgE sensitization 
IgE sensitization refers to the presence of allergen-specific IgE antibodies in the body. In 
general, two tests are used to identify sensitization, skin prick tests (SPT) and measuring the 
presence of antibodies (IgE) from a blood test. Phadiatop® and fx5® are both lab tests 
developed to identify mixtures of specific antibodies within blood. Higher levels of IgE in 
blood increases the likelihood of presenting with symptoms of allergic diseases but this is not 
always the case.   
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1.1.7 Lung function 
1.1.7.1 Dynamic spirometry 
In epidemiological studies, lung function is often assessed as an objective measurement for 
lung growth, development, or impairment. Dynamic spirometry is the most common 
pulmonary function test, and is routinely used in clinical and research settings. Spirometry 
measures the speed (flow) and amount (volume) of air an individual inhales or exhales over 
time, and generates a flow-volume loop (Figure 1
27
).
28
 Using standardized methods 
developed by the American Thoracic Society and European Respiratory Society, spirometry 
provides reliable and reproducible information regarding lung capacity and function.
28
 The 
most frequently used measures from spirometry are forced vital capacity (FVC), forced 
expiratory volume in one second (FEV1), and the ratio of FEV1/FVC.  
FVC is the maximum volume of air exhaled with maximal forced effort from complete 
inspiration and represents the size of the lungs.
28
 FEV1 is the amount of air exhaled in one 
second during the FVC manoeuver and impaired values represent the degree of air flow 
limitation. The ratio of these two measures (FEV1/FVC) is presented as a percent and is lower 
in individuals with obstructive lung disease. Other flows or volume measurements can be 
obtained at various time points during the FVC manoeuver such as peak expiratory flow 
(PEF).     
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1. Example of a flow volume loop. Adapted from SPhotographer.  
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1.1.7.2 Impulse oscillometry  
Unlike dynamic spirometry, which requires maximal patient effort, impulse oscillometry 
(IOS) is an effort-independent pulmonary function test performed during tidal breathing. IOS 
provides a compliment to spirometry as it can differentiate between large and small airway 
effects.
29 30
 IOS is a form of forced oscillation technique which means that pressure 
oscillations are forced upon the respiratory system and that information about the mechanical 
properties of the respiratory system can be derived from the "opposing forces" that the 
respiratory system exerts. These are resistance (R) and reactance (X). By separating data with 
respect to frequency of signals more detailed information about the properties of the 
respiratory system can be derived, such as the mean value of resistance at 5 Hertz (Hz) (R5), 
resistance at 20 Hz (R20), frequency dependence of resistance (R5-20), and the square root of 
the area of reactance (AX
0.5
). Higher frequencies (>20 Hz) reach the large and intermediates 
airways and lower frequencies (<15 Hz) penetrate the peripheral and conductive airways.  
R5-R20 (resistance at 5 Hz minus the resistance at 20 Hz) is considered to reflect the 
heterogeneous distribution of peripheral resistance and presence of small airway 
dysfunction.
29
 The area of reactance (AX) is the integrated value of reactance with respect to 
frequency from 5 Hz to resonant frequency. Taking the square root of AX (AX
0.5
) will 
linearize this variable and create a more robust reactance index than any reactance value at a 
particular frequency. In most cases there is good correlation between R5-R20 and AX
0.5
, even 
in a single subject. So despite that fact that R5-R20 and AX
0.5
 concern different physical or 
mechanical properties of the respiratory system they can cross-confirm each other. 
  
  5 
1.2 TOBACCO SMOKE 
1.2.1 History 
The tobacco plant has been growing wild in the Americas for nearly 8000 years, and about 
2000 years ago humans began chewing and smoking tobacco leaves during cultural and 
religious ceremonies.
31
 Following his voyage to the Americas, Christopher Columbus 
returned with tobacco seeds to Europe, and by 1531 tobacco was grown for the first time in 
Europe.
31
 Initially smoking was a masculine habit and became widespread during the world 
wars. Following World War II, smoking among women became more common, and was 
advertised as a sign of independence, sophistication, and being well educated.
32
 Tobacco was 
first considered to be deleterious to health by an English author in 1602 who reported in an 
essay about chimney sweeps, suggesting that disease was caused by soot and tobacco smoke 
could have analogous consequences.
31
 By the 1950’s and 1960’s tobacco smoking was 
causally linked to a wide range of medical conditions. Today we know that the burning of 
tobacco leaves emits more than 4500 chemicals, of which many are known to be carcinogenic 
and many others toxic.
33
 Of the thousands of compounds emitted by burning tobacco, 
identifying which components influence the pathogenesis of disease is challenging. Presently 
cigarette smoking is a global epidemic, and is a leading preventable cause of death and 
disability.
33
  
1.2.2 Exposure during pregnancy 
Maternal smoking during pregnancy is consistently associated with numerous detrimental 
health effects, including but not limited to infant mortality, pre-term birth, growth retardation, 
respiratory infections, low birthweight, and sudden infant death syndrome (SIDS).
34 35
 
Despite continued health campaigns and prenatal counseling some mothers continue to 
smoke during pregnancy, and globally the prevalence varies from less than 10% to over 
30%.
36
 In high-income societies the number of pregnant women smoking is waning, but in 
low-income countries this number is on the rise.
37
  
A fetus is exposed to the same amount of nicotine as an active smoker, which is associated 
with reduced uterine blood flow through vasoconstriction resulting in lower oxygen in the 
placenta.
38
 As a result of reduced blood flow, intrauterine growth retardation leads to lower 
birthweight, both of which are associated with the development of the respiratory system.
39
 
Nicotine induces changes in lung architecture and function, and exposure to maternal 
smoking during pregnancy is linked with preschool wheeze, asthma, reduced lung function, 
and airway responsiveness in children.
40-46
  
1.2.3 SHS exposure  
Secondhand tobacco smoke (SHS), also referred to as passive smoking or environmental 
tobacco smoke, is a complex aerosol made up of carcinogenic, mutagenic, and toxic 
compounds. There are two types of SHS, mainstream smoke and sidestream smoke. 
Mainstream smoke is the tobacco smoke that is created when a smoker inhales the burning 
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tobacco and then exhales. Sidestream smoke is the smoke components that are released from 
the end of the smoldering tobacco product. Various toxic gasses, such as acrolein, benzene, 
carbon monoxide, and formaldehyde are found in sidestream smoke, many of which are 
carcinogenic and cause non-cancer health related effects.
47
 Over five million deaths are 
attributable to smoking worldwide, and over 600,000 are linked to SHS exposure yearly.
48
 
According to a 2006 US Surgeon General Report, “The scientific evidence indicates that 
there is no risk-free level of exposure to secondhand smoke”.49     
Many children who are exposed to maternal smoking during pregnancy are also exposed to 
SHS postnatally, and more than half of mothers who abstain from smoking during pregnancy 
relapse within the first six months, and another 80-90% relapse within the first year.
37 50
 SHS 
is one of the most critical and predominant exposures in the indoor environment, and 
approximately 40% of children worldwide are exposed to SHS.
51
 Children are different from 
adults, in that their respiratory system is still developing  and are more sensitive to 
environmental pollutants such as SHS.
47
 SHS is associated with a plethora of adverse health 
outcomes in infants and children including SIDS, lower respiratory tract infections, asthma, 
rhinitis, eczema, and other chronic respiratory symptoms.
36 47 52-55
 The majority of exposure 
to SHS occurs in early infancy and during preschool ages, when children spend substantial 
time in close vicinity of their parents. Neonates and children exert little control over their 
environment, and therefore are particularly susceptible to the harmful effects of SHS. 
Exposure can begin early in life, starting from exposure to maternal smoking during 
pregnancy and often continues into early childhood, which makes it challenging to tease apart 
the effects of tobacco smoke exposure in pregnancy from postpartum exposure.  
Although outside the scope of this thesis, for completeness another aspect of cigarette 
smoking is third-hand smoke (THS). THS is the set of chemical compounds and components 
that linger long after cigarettes are extinguished.
56
 For example, pollutants from residual 
tobacco smoke can remain on surfaces, clothes, and even the smoker himself/herself in hair 
or on hands.
57 58
 Toxins and pollutants identified to date include nicotine, phenol, cresols, 
naphthalene, 3-ethenylpyridine, and nitrosamines.
58
 There is some research which suggests 
an association between third-hand smoke with respiratory and nasal symptoms.
56 58-61
  
1.2.4 Prevalence of tobacco use and SHS in Sweden 
In Sweden, the prevalence of smoking has declined in recent decades and nine percent of 
adults were daily smokers in 2015.
62
 Smoking is somewhat more common among females 
compared to males. Maternal smoking during pregnancy has also declined in Sweden, and a 
survey in 2011 indicated that 5% of mothers smoked at some point during their pregnancy 
which was down from 9.5% in 2003.
63
 Exposure to SHS has also reduced coinciding with the 
decline in smoking rates, and in 2001 around 11% of 12 year-olds, 9.6% of four-year-olds, 
and 7.5% of eight month olds had at least one parent who smoked. There are large 
socioeconomic differences in the prevalence of smoking. Smoking is almost three times as 
common among individuals without high school educations, compared to persons with a 
  7 
university degree.
64
 The use of smokeless tobacco (snus/moist snuff) is more common among 
males (19%), compared to females (4%).
64
   
1.2.5 Tobacco smoke exposure in relation to allergic diseases and lung 
function in childhood and adolescence   
1.2.5.1 Asthma 
Exposure to tobacco smoking has been linked with both exacerbations as well as the 
development of asthma in young children.
52 65-68
 Studies focusing on whether tobacco smoke 
exposure contributes to the etiology of asthma in young children concluded that exposure not 
only increased symptoms but contributes significantly to the development of wheeze and 
asthma.
65 66 69-71
 Studies have also attempted to disentangle which exposure presents the 
greatest risk, maternal smoking during pregnancy or postnatal exposure to tobacco smoke. In 
a prospective Swedish birth cohort study, Lannerö et al. found a twofold increased odds of 
wheezing in children up to two years of age who had been exposed to maternal smoking 
during pregnancy but not thereafter.
71
 Furthermore, a meta-analysis of eight European birth 
cohorts was able to show that maternal smoking during pregnancy alone without exposure 
postpartum conveyed excess risk of wheezing and asthma in preschool age children.
42
 In this 
meta-analysis Neuman et al. also observed elevated risks of asthma in children exposed to 
maternal smoking during the first year of life, but this was not statistically significant. Other 
studies have suggested elevated risk of asthma in children exposed to parental smoking in 
early life.
40 67 72
  
Whether the harmful effect of early exposure to tobacco smoke persists into adolescence has 
yet to be elucidated, and few longitudinal studies have assessed the risk of adolescent-onset 
asthma in relation to maternal smoking during pregnancy or SHS exposure. Of the studies 
that have been published, the findings have been mixed. A Danish birth cohort that follow 
children up to 14-18 years of age observed no significantly elevated risk of asthma in those 
exposed during pregnancy, postnatally, or both.
73
 In an Australian birth cohort study, 
Hollams et al. found a nearly twofold increased odds of current asthma at 14 years of age in 
children who had been exposed to maternal smoking during pregnancy.
74
 Similarly, a 
German birth cohort followed for 20 years found a 1.7 times increased odds of developing 
incident asthma in those exposed to maternal smoking during pregnancy.
75
 They also found 
no association between exposure to SHS in the first three years of life and the incidence of 
asthma up to 20 years of age.
75
 No increased risk between lifetime SHS exposure and asthma 
at ages 4-17 years was seen in a Dutch cohort study.
76
    
1.2.5.2 Rhinitis 
The literature on the effects of tobacco smoke exposure and the development of rhinitis are 
more inconsistent and sparse than that of asthma. A large multicenter and multi-country 
cross-sectional analysis studying the effects of SHS on allergic diseases, in two groups of 
children ages 6-7 and 13-14 years, was conducted as part of the International Study of 
Asthma and Allergies in Childhood (ISAAC) initiative. This study observed significantly 
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elevated risks of current rhinoconjunctivitis in both age groups among those subjects exposed 
to maternal smoking in the first year of life, as well as for current maternal or paternal 
smoking.
77
 In a Danish cohort study, Magnusson et al. did not find significant associations 
between hayfever (rhinitis) and exposure to prenatal or postnatal tobacco smoke exposure.
73
 
Similarly, a German birth cohort study followed up to ten years of age found no significant 
association between maternal smoking and allergic rhinitis.
78
 A recent systematic review and 
meta-analysis indicated slightly elevated risk of rhinitis (OR 1.09, 95% CI 1.04-1.14) in 
children and adolescents exposed to parental smoking.
54
 A cross-sectional study from Turkey 
also indicated that children exposed to maternal smoking during pregnancy had increased 
odds of current rhinoconjunctivitis in children at age 9-11 years.
79
 There is no consensus on 
the role tobacco smoke plays in the development of rhinitis and there is limited literature 
related to the long-term effects of tobacco smoke exposure and the development of rhinitis up 
to adolescence. 
1.2.5.3 Eczema 
There is a growing body of evidence linking tobacco smoke exposure and eczema. Krämer 
and colleagues observed an association between an objective biomarker of SHS exposure, 
urinary cotinine to creatine ratio (CCR), and eczema. They found that for every 100 ng mg
-1
 
of CCR  there was a nearly twofold increase in eczema among preschool age children.
16
 A 
study of cord blood cotinine at birth and eczema at two years of age in Taiwanese children 
indicated a fivefold increased risk of atopic dermatitis in those exposed to the 75
th
 percentile 
of cotinine levels.
80
 Furthermore, consistently elevated risk estimates of current eczema were 
seen in a large cross-sectional study of 6-7 year olds and 13-14 years olds exposed to both 
maternal smoking in the first year as well as current parental smoking.
72
 A Swedish birth 
cohort suggested increased risk of eczema in four year old children exposed to maternal 
smoking in pregnancy, parental smoking during the child’s first months, or both, but only in 
those children with concurrent IgE sensitization.
81
 Conversely, Magnusson and colleagues 
observed that children exposed in pregnancy had slightly reduced risk of eczema at ages 14-
18.
73
 Similarly, Ludvigsson and colleagues found that children exposed to parental smoking 
were less likely to develop atopic dermatitis.
82
 In summary, the role of tobacco smoke 
exposure and the development of eczema remains controversial, due to limitations in study 
design, length of follow-up, variations in outcome definitions, and exposure assessment.  
1.2.5.4 IgE sensitization 
SHS exposure is associated with respiratory and allergic disease in children, but the influence 
of tobacco smoke exposure on IgE mediated sensitization is uncertain.
59
 Exposure to tobacco 
smoke is suggested to have immunomodulatory effects and is presumed to play a role in the 
development of allergic sensitization.
59 83
 Some studies have reported increased risks for any 
allergen sensitization
78 84
, while others report increased risks only for food allergen 
sensitization.
85-87
 Studies have also reported inverse
83 88 89
 or null associations for inhalant 
allergens
90
 and there is inconsistent data on the role of heredity.
78 83 84 91
 A recent systematic 
review and meta-analysis in young children and adolescents indicated that SHS is associated 
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with higher total IgE concentrations, the presence of specific IgE to common allergens, and 
positive skin prick test against common allergens.
92
 These findings were mostly apparent in 
children under seven years of age. Reasons for such conflicting results include inadequate 
control of confounding, the aggregation of inhalant and food allergens together, failure to 
consider or control for possible differing effects of SHS between those with and without 
family history of atopy, or maternal versus paternal smoking.
83 91
  Separating the effects of 
maternal smoking during pregnancy and postnatal SHS exposure is difficult, but important 
nonetheless, since the etiological mechanisms may differ depending on timing of exposure.  
1.2.5.5 Lung function 
In 1986 the US Surgeon General concluded that, “available data demonstrate that maternal 
smoking reduces lung function in young children”, and this report has been corroborated by 
multiple studies since.
93-95
 The literature also suggests reductions in lung function related to 
SHS exposure in young children.
95 96
 A cross-sectional study of children ages 6-15 years 
observed that deficits in the small airways was inversely associated with the number of 
cigarettes smoked by the parents.
97
 In line with this, a large multinational study of children 6-
12 years suggested reduced lung function measures in children exposed during pregnancy and 
in early childhood.
98
 Similarly, in a well characterized Australian birth cohort study, maternal 
smoking in pregnancy was related to reduced lung function in 14 year old children.
74
 Regular 
SHS exposure among school age children has also been linked with reduced lung function.
99
 
Although exposure to tobacco smoking during the perinatal period has been consistently 
associated with impaired pulmonary function in infants and children, it is unclear if 
pulmonary function is affected in adolescence. In general, lung growth and functional 
development continues until the mid-20’s100, and failure to reach maximal lung growth can 
have lasting deleterious effects.
101 102
 Data on the independent effect of adolescent smoking 
on lung function accounting for maternal smoking during pregnancy are even more limited, 
especially utilizing prospectively collected data from birth to adolescence.
103 104
 Furthermore, 
it remains unclear if interactions between exposure during pregnancy and personal smoking 
in adolescence exist. 
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1.3 INDOOR ENVIRONMENT 
1.3.1 Indoor mold and dampness 
Mold and moisture and can enter homes in various ways. Materials used during construction 
can be unsheltered from precipitation or not given ample drying time prior to construction, 
and moisture is then “built into the structure”. Moisture can also enter homes through leaks in 
roofs, windows, or even leaky plumbing between walls. Occupants also generate humidity, 
and coupled with poor ventilation can lead to moisture related problems. Building types, 
construction practices, ventilation rates, and climate all influence the amount of moisture 
buildup in a home.  
Damp environments enhance the growth and proliferation of fungal components such as 
spores, fungal fragments, gram-negative bacteria, volatile organic compounds (VOC), and β-
glucans which are associated with allergic and non-allergic outcomes.
105 106
 Excessive 
moisture can promote deterioration of some building materials which can release toxic 
substances. The presence of mold and dampness in dwellings is common, with estimates 
ranging from 18% to 50% this is a major indoor problem worldwide.
107 108
 Consequently, a 
significant percentage of the globe is exposed to mold or dampness-related exposures.
109
 
Epidemiological studies have found increased risk of wheeze, asthma, rhinitis, and 
respiratory symptoms in children exposed to indoor mold or dampness.
106 110-115
 Still, there 
remains a lack of studies with quantitative measurements of fungi and other microbiologic 
exposures, and studies have been inconsistent.
116
 Moreover, the role of mold or dampness 
exposure in relation to the persistence and late-onset of allergic diseases is not fully 
understood.   
1.3.2 Indoor mold and dampness in Sweden 
In Sweden building materials, structure, and technologies have varied over time, and various 
building techniques are associated with different periods. A building boom occurred between 
1961 and 1975, and many high-rise buildings were rapidly constructed with basements and 
only exhaust ventilation, and these homes have the highest reported dampness.
117 118
  During 
the 1970’s increased importance on energy conservation required increased insulation and 
multilayer walls, which can be prone to moisture buildup. In 1977 a self-leveling mortar was 
introduced, but was then no longer used after 1983, due to increased chemical emissions 
when this mortar encountered moisture.
119
 Studies have suggested that living in homes using 
this mortar had higher prevalences of mucosal inflammation and asthma.
120
   
1.3.3 Mold and dampness exposure in relation to allergic disease in 
childhood and adolescence 
1.3.3.1 Asthma 
There is a growing body of evidence linking mold and dampness-related agents with 
respiratory symptoms and asthma in children. The vast majority of evidence comes from 
cross-sectional and case control studies, but a meta-analysis of eight European birth cohorts 
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indicated that children exposed to early visible mold and/or dampness had increased risk of 
asthma up to three years of age.
15
 This study also suggested a nonsignificantly increased risk 
of asthma in children ages 6-8 years and 3-10 years.
15
 Another systematic review of cohort 
and incident case-control studies which aimed to assess the development of incident asthma, 
found a 1.5 increased odds of asthma in children exposed to any sign of mold or dampness.
121
 
However, in a German birth cohort, no increased risk of asthma at age 20 years was observed 
among those children exposed to mold spots at three months of age.
75
 In a recently published 
systematic review and meta-analysis, the presence of certain species of fungi, Penicillium, 
Aspergillus, and Cladosporium, were associated with increased risk of developing asthma 
symptoms in children and adults.
122
 A limited number of prospective studies have been 
conducted, and even fewer have investigated the risk of asthma as children reach adolescence 
as well as the persistence or late-onset disease phenotypes. Thus, it is unclear if early mold 
and dampness exposure in children contributes to the development of asthma up to 
adolescence or simply exacerbates preexisting respiratory conditions.
116
   
1.3.3.2 Rhinitis 
The association between residential dampness and mold exposure and rhinitis tends to 
provide a consistent picture of increased risks in children, with the majority of studies 
observing elevated effect estimates for a variety of dampness-related exposures.
15 121 123-129
 In 
a large cross-sectional analysis of elementary and middle school age children in Italy, Simoni 
and colleagues found that early exposure to mold or dampness was associated with 
rhinoconjunctivitis.
123
 Among adolescents exposed to both early and current signs of mold or 
dampness, risk estimates for rhinoconjunctivitis were even higher.
123
 Similar results were 
seen in a meta-analysis of eight well characterized European birth cohorts; early visible mold 
exposure (0-2 years) was associated with allergic rhinitis symptoms up to 10 years of age.
15
 
Nevertheless, there is a lack of prospective studies which examine the long term effects of 
early or current dampness-related exposure, and whether they continue to contribute to the 
development and persistence of rhinitis.  
1.3.3.3 IgE sensitization 
There is scarce information on the association between IgE sensitization in relation to 
dampness-related exposures, and of these studies the results are inconclusive.
130
 Antova and 
colleagues did find increased “sensitivity to inhaled allergens” in children exposed to mold 
ever.
125
 However, this was not based on skin prick testing or the presence of IgE. Taken 
together, there are indications of increased risk but the evidence is too inconsistent to draw 
conclusions.
111 131-133
 Additional studies are necessary to evaluate this association more 
closely.  
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2 AIMS 
The overarching aim of this work is to study the association between tobacco smoke or the 
indoor environment and development of allergic diseases as well as lung function in children 
and adolescents. The specific aims in this thesis are as follows: 
 To study the association between maternal smoking during pregnancy and allergic 
diseases as well as lung function up to adolescence.  
 
 To study the association between SHS exposure during infancy or childhood and 
allergic diseases as well as lung function up to adolescence.  
 
 To investigate the association between adolescent smoking and lung function at age 
16 years. 
 
 To assess the association between exposure to indicators of mold or dampness in the 
home and development of allergic diseases up to adolescence.  
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3 METHODS 
3.1 DATA SOURCES 
Studies I, II, IV, and V used data exclusively from the BAMSE cohort study and study III 
utilized individual participant data from five European birth cohort studies (including 
BAMSE) which were part of the MeDALL consortium.   
3.1.1 BAMSE birth cohort 
The Barn (Children), Allergi (Allergy), Miljö (Environment), Stockholm, Epidemiologi 
(Epidemiology) (BAMSE) birth cohort is an ongoing prospective birth cohort study which 
began in February 1994. At inception, 4089 participants were recruited from four predefined 
areas of Stockholm (Järfälla, Solna, Sundbyberg, and parts of Stockholm inner city) (Figure 
2).
134
 The rational for this was to capture various exposure characteristics including, but not 
limited to, housing types, urban/suburban, socio-demographic characteristics, and varying 
levels of air pollution.  
 
 
 
 
  
 
  
Järfälla 
Solna 
Northern part  
of inner-city 
Sundbyberg 
Europe Stockholm County 
Figure 2. The four predefined recruitment areas of Stockholm County, Sweden included in the 
BAMSE birth cohort. Maps adapted from © OpenStreetMap contributors and created by Andrei Pyko. 
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Children born in the study area  
during the recruitment period 
N = 7221 
Study base 
N = 4089 
Excluded according to study plan: 
 
Planned to move within one year: n = 699 
Insufficient ascertainment of Swedish 
language: n = 331 
Older sibling enrolled: n = 169 
Severe illness: n = 57 
 
Total: n = 1256 
Unknown address  
n = 477 
Failed to answer inclusion 
questionnaire  
n = 897 
Declined participation  
n = 502 
3.1.1.1 Enrollment 
Enrollment commenced in February 1994 and continued to 1996, and during this period 7221 
children were born in the study areas. In Sweden, all newborns are invited to the children’s 
healthcare center for a physical exam, and 99% of the children under two years of age 
attend.
135
  During the child’s first visit at the children’s healthcare center, parents were invited 
to participate in BAMSE. Of the 7221 children eligible for the study, 477 could not be 
contacted, 502 declined participation, 897 never answered the questionnaire, and 1256 were 
actively excluded in accordance to the study plan. These 1256 actively excluded individuals 
were either moving within a year (n=699), did not sufficiently understand Swedish (n=331), 
already had a sibling enrolled (n=169), or the child was seriously ill (n=57). At the end of 
recruitment 4089 children were included, 75% of all eligible infants. Figure 3 summarizes 
this recruitment.  
 
 
 
 
At a median age of two months, parents of the 4089 infants (2065 males and 2024 females) 
completed the baseline questionnaire. This questionnaire queried information on various 
environmental and behavioral factors including smoking history, housing characteristics, 
socio-demographics, and parental history of allergic disease. In 1996, an abridged 
questionnaire was sent to non-responders and participants who were actively excluded. To 
understand if and how these non-responders differed from those included, a short survey 
Figure 3. Summary of recruitment in the BAMSE birth cohort.  
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querying parental history of allergic disease, pet ownership, and tobacco smoking habits was 
sent out, and an overall response rate of 67% was achieved.
134
 Data gathered from this 
questionnaire indicated that non-participants and those actively excluded were more 
commonly exposed to tobacco smoke than the participating families (maternal smoking – 
18% vs. 9%; paternal smoking – 23% vs. 17%), but no differences were seen with regards to 
parental history of allergic disease.
134
  
3.1.1.2 Follow-up 
Subsequent follow-up questionnaires were sent out to the baseline participants (4089) at ages 
1, 2, 4, 8, 12, and 16 years of age with response rates of 96%, 94%, 91%, 84%, 82%, and 
78% respectively (Figure 4).  
In conjunction with questionnaires, at ages 4, 8, and 16 years study subjects were invited to 
participate in clinical examinations. At these examinations blood draws with venipunctures 
and lung function testing were performed. A summary of the follow-ups is illustrated in 
Figure 4. 
 
 
 
 
  
1-year questionnaire  
N = 3925 (96%) 
2-year questionnaire 
N = 3843 (94%) 
4-year questionnaire 
N = 3729 (91%) 
Blood: 2614 (64%) 
8-year questionnaire 
N = 3417 (84%) 
Spirometry: 2613 (64%) 
Blood: 2470 (60%) 
12-year questionnaire 
Parent: N = 3356 (82%)  
Adolescent: N = 2795 (68%) 
16-year questionnaire  
Parent: N = 3181 (78%) 
Adolescent: N = 3115 (76%) 
Blood: 2547 (63%) 
Spirometry/Impulse oscillometry: 2605 
Baseline (2 months) 
questionnaire 
N = 4089 (100%) 
1994 
1995 
1996 
1997 
1998 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
2007 
2008 
2009 
2010 
2011 
2012 
 
Year 
Figure 4. Flow chart of the BAMSE cohort follow-up periods and data collected.  
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3.1.2 The MeDALL consortium 
The Mechanisms for the Development of Allergy (MeDALL) consortium, a Seventh 
Framework Program European Union project, began in 2010 and was organized to generate 
novel knowledge on the mechanisms of the initiation of allergy.
136-138
 The MeDALL 
consortium included 14 ongoing European birth cohorts initiated between 1990-1997. Study 
III included five European birth cohorts (including BAMSE) which had follow-ups into 
adolescence and data on exposures and outcomes. The following cohorts were included in 
study III, BAMSE (single-center, Sweden),
134
 GINIplus (multicenter, Germany),
139
 LISAplus 
(multicenter, Germany),
140
 MAS (multicenter, Germany),
141
 and PIAMA (multicenter, The 
Netherlands).
142
 An overview of birth cohorts included in study III is presented in Table 1.  
 
3.2 STUDY POPULATIONS 
The final study population of study I comprised children who participated in three or more 
follow-ups, had complete information on maternal smoking during pregnancy or SHS during 
infancy, and had information about any allergic disease outcome from any age, which 
resulted in 3798 participants (93% of the baseline cohort). This inclusion criteria was chosen 
to promote stable and robust longitudinal analyses.  
In study II we included 3316 participants (81% of the baseline cohort) who had complete 
information on maternal smoking during pregnancy or SHS exposure during infancy, 
confounders, and gave a blood sample at age 4, 8, or 16 years.  
Study III was based on the MeDALL consortium and involved 10860 participants (59% of 
the 18451 children at recruitment) for whom information was available on maternal smoking 
during pregnancy and/or infancy, and asthma or rhinoconjunctivitis between ages 14-16 years 
(Table 1).   
 
Table 1. Overview of included birth cohorts from the MeDALL consortium. 
Cohort acronym Country Years of 
recruitment 
Number of 
children at 
recruitment 
N 
Number included 
in final analyses 
n (%) 
BAMSE Sweden 1994-1996 4089 3112 (76.1) 
GINIplus Germany 1995-1998 5991 2956 (49.3) 
LISAplus Germany 1997-1999 3094 1713 (55.4) 
MAS Germany 1990 1314 560 (42.6) 
PIAMA The Netherlands 1996-1997 3963 2519 (63.6) 
Total   18451 10860 
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In study IV the final study population comprised participants with a valid spirometry 
measure, information on smoking habits at age 16 years, and covariates – 2295 participants 
(56% of the baseline cohort). For analyses related to saliva cotinine concentrations, 
participants with a valid lung function measure, a saliva cotinine sample, and covariates were 
included (N=1523). 
The final study population of study V comprised participants who provided a baseline 
response to any mold or dampness indicator and participated in three or more follow-ups, 
which resulted in 3293 participants (81% of the baseline cohort). 
 
3.3 EXPOSURE AND OUTCOME DEFINITIONS 
3.3.1 Background characteristics and variables 
Background variables for studies I-V are summarized in Table 2. The majority of baseline 
characteristics (BAMSE) were queried from the initial questionnaire at a median age of two 
months.  Baseline and background characteristics from the other cohorts in study III were 
also gathered shortly before (PIAMA) or after birth (GINIplus, LISAplus, MAS).  
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Table 2. Definitions of background characteristics and covariates in studies I to V. 
Variable  Variable definition Study  
Sex Biological sex of participant (male vs. female). I, III, IV, V 
Age Participant’s age at lung function assessment in years. IV 
Height Participant’s height at lung function assessment in centimeters. IV 
Birth weight Birthweight of the child in grams. III 
Gestational age Gestational age of the child in weeks. III 
Maternal age Mother’s age at birth of child (<26 years vs. ≥26 years). V 
Breastfeeding Exclusive breastfeeding for a duration of ≥4 months (yes vs. no). III 
Parental history of 
allergic disease 
Mother and/or father reporting doctor’s diagnosis of asthma or 
hay fever (yes vs. no).  
I, II,III, V 
Socioeconomic status Categorized base on parental occupation according to the Nordic 
standard occupational classification and divided into manual 
workers (low) and non-manual workers (high). 
I, II, V 
Parental education 
level 
Based on the highest educational level of either parent. Divided 
into low – primary school, lower vocational education, or lower 
secondary education; intermediate – intermediate vocational 
education or intermediate/higher secondary education; high – 
higher vocational education or university degree. 
III 
Mean income Mean income in the neighborhood and are defined on the basis of 
small-area market statistics from Statistics Sweden 
(http://www.scb.se).  
I* 
Early day-care 
attendance 
Did the child attend nursery or day-care with other children at 
any time from ages 0, 1, and/or 2 years (yes vs. no). 
III 
Older siblings The presence of at least one older sibling at the time of birth (yes 
vs. no).  
III, V 
Study center GINIplus, LISAplus, and PIAMA were all multicenter studies. 
GINIplus consisted of Munich, Bavaria, Wesel, and North-
Rhine-Westfalia. LISAplus consisted of Munich, Leipzig, Wesel, 
and Bad Honnef. PIAMA was divided into North – Groningen, 
Friesland, Drenthe; Central – Utrecht, Gelderland; and West – 
Rotterdam and surrounding municipalities. 
III 
Study arm GINIplus and PIAMA had an observational and intervention 
study arm in these cohorts. GINIplus had an arm that delayed the 
introduction of solid foods
143
 and PIAMA had an arm that 
distributed mite impermeable mattress covers.
144
 
III 
Cohort Birth cohort (BAMSE, GINIplus, LISAplus, MAS, PIAMA). III 
Maternal smoking 
during pregnancy 
Mother smoking at least one cigarette daily at any trimester of 
gestation (yes vs. no).  
V 
Parental smoking 
during infancy 
Mother and/or father smoking at least one cigarette daily at 
baseline questionnaire (2 months) (yes vs. no). 
V 
Secondhand smoke 
throughout childhood 
Exposure to SHS at any age after year one.  I,II,III 
Mold or dampness in 
dwelling 
Presence of signs of mold or dampness in the home at ages 0, 1, 
and/or 2 years (yes vs. no). 
III 
* Only used in sensitivity analyses.  
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3.3.2 Exposure assessment 
3.3.2.1 Tobacco smoke  
For studies I, II, and IV tobacco smoking was assessed via questionnaires. For prenatal 
exposure only maternal smoking habits were queried at baseline. The number of cigarettes 
smoked was also ascertained for each trimester. At the 12-year follow-up fathers were asked 
retrospectively if they smoked during their child’s pregnancy (BAMSE), but these data were 
only used in sensitivity analyses and some results are presented in section 4.9.1.   
In BAMSE, SHS exposure was assessed at baseline, 1, 2, 4, 8, 12, and 16 years for both 
mothers and fathers. The number of cigarettes smoked per day was also ascertained and used 
in dose-response analyses. At age 16 years participants answered their own questionnaire 
which also gathered information on personal smoking habits. Table 3 outlines all tobacco 
smoke exposure related variables and definitions used in BAMSE. Smoke exposure was 
defined as smoking cigarettes, cigars, cigarillos, or pipe smoking. 
 
  
 
 
 
 
 
 
 
In study III each cohort defined tobacco smoking in a relatively similar manner and is 
summarized in Table 4. Smoke exposure was defined as smoking cigarettes, cigars, cigarillos, 
or pipe smoking. In all cohorts prenatal smoking was ascertained during pregnancy or shortly 
thereafter, and all cohorts had information on the number of cigarettes smoked by the mother 
for each trimester of pregnancy. 
 
Table 3. Definitions of tobacco smoke exposure in BAMSE (Studies I, II, and 
IV). 
Variable Definition Study 
Maternal smoking during 
pregnancy (in utero) 
Maternal smoking ≥1 cigarette daily 
at any time during pregnancy. 
I, II, IV 
SHS during infancy  Maternal or paternal smoking ≥1 
cigarette daily at baseline 
questionnaire.  
I, II, IV 
SHS at ages 1, 2, 4, 8, 12, 
and 16 
Maternal or paternal smoking ≥1 
cigarette daily at the time of the 
respective follow-up questionnaire. 
I, II, IV 
Adolescent smoking Any smoking at age 16 years. IV 
Daily smoking Smoking at least one cigarette per 
day. 
IV 
Occasional smoking Smoking less than one cigarette per 
day.  
IV 
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Table 4. Definitions of tobacco smoke exposure in MeDALL (Study III). 
 Maternal smoking SHS exposure 
Birth cohort Maternal Smoking 
during pregnancy 
Infancy 
(first year of life) 
When children were 
ages 1-2 years 
When children were 
ages 4-6 years 
When children were 
ages 8-10 years 
When children were 
ages 14-16 years 
BAMSE Mother smoked at 
least 1 cig/day during 
any trimester of 
pregnancy. 
Mother, father, or 
others actively smoke 
at home at age 2 
months. 
Mother, father, or 
others actively smoke 
at home at age 2 year. 
Mother, father, or 
others actively smoke 
at home at age 4 
years. 
Mother, father, or 
others actively smoke 
at home at age 8 
years. 
Mother, father, or 
others actively smoke 
at home at age 16 
years. 
GINIplus Mother smoked 
during any trimester 
of pregnancy. 
Mother actively 
smoking inside the 
home between age 5 
and 12 months. 
Smoking inside the 
home (in general) at 
age 2 years. 
Mother, father, or 
others actively smoke 
inside the home at 
age 6 years. 
Mother, father, or 
others actively smoke 
inside the home at 
age 10 years. 
Mother, father, or 
others actively smoke 
inside the home at 
age 15 years. 
LISAplus Mother smoked 
during any trimester 
of pregnancy. 
Mother, father, or 
others actively smoke 
inside the home at 
age 1 year. 
Mother, father, or 
others actively smoke 
inside the home at 
age 2 years. 
Mother, father, or 
others actively smoke 
inside the home at 
age 6 years. 
Mother, father, or 
others actively smoke 
inside the home at 
age 10 years. 
Mother, father, or 
others actively smoke 
inside the home at 
age 15 years. 
MAS Mother smoked 
during any trimester 
of pregnancy. 
Mother, father, or 
others actively smoke 
inside the home at 
age 1 month. 
Mother, father, or 
others actively smoke 
inside the home at 
age 18 months. 
Mother, father, or 
others actively smoke 
inside the home at 
age 4 years. 
Mother, father, or 
others actively smoke 
inside the home at 
age 9 years. 
No data 
PIAMA Mother smoked 
during any trimester 
of pregnancy. 
Cigarettes, pipes, 
cigars smoked in the 
house by mother, 
father and/or other 
household member at 
age 3 months. 
Cigarettes, pipes, 
cigars smoked in the 
house by mother, 
father and/or other 
household member at 
age 2 years. 
Cigarettes, pipes, 
cigars smoked in the 
house by mother, 
father and/or other 
household member at 
age 4 years. 
Cigarettes, pipes, 
cigars smoked in the 
house by mother, 
father and/or other 
household member at 
age 8 years. 
Cigarettes, pipes, 
cigars smoked in the 
house by mother, 
father and/or other 
household member at 
age 14 years. 
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3.3.2.2 Saliva cotinine 
Cotinine is a widely accepted quantitative biomarker of recent uptake of nicotine which may 
result from active or passive smoking.
145
 Saliva samples were collected when participants 
were 16 years of age. Saliva collection kits were distributed at the clinical examination at age 
16 years along with detailed instructions. Saliva was collected in the morning and evening 
time (prior to dental hygiene) using sterile dental rolls (braided cotton dental rolls; 
Salivetter®, SARSTEDT AG & Co., D-51582 Nümbrecht). Participants were instructed to 
keep the roll in their mouths until it was saturated with saliva and then place it in the pre-
labeled sample tube and sent directly to the laboratory via post. Samples were centrifuged and 
stored at -80 degrees Celsius. Evening samples were analyzed using the Salimetrics® 
cotinine kit (Salimetrics Europe, Ltd, Suffolk, UK) with a detection limit of 0.8 ng/ml.  
The distribution of saliva cotinine concentrations in nonsmokers was positively skewed, 
therefore the data were log-transformed, and we assigned a value of 0.4 ng/ml, half the 
detection limit, to undetectable concentrations.
145
 Based on prior literature a cut-off of ≥12 
ng/ml was used to discriminate active smokers from nonsmokers.
146
 A total of 20 evening 
samples had too little saliva and were excluded from analysis. 
3.3.2.3 Mold and dampness 
In study V indoor environmental exposures were based on parental answers at the baseline 
questionnaire. We defined four variables to assess mold or dampness in the home from the 
following questions
115
: 
Mold odor—‘Is there, or has there ever been, a smell of mildew in the home?’ 
Visible mold—‘Has there been any visible mold in the home in the past year (prior to the date 
of the baseline questionnaire)?’ 
Dampness damage—‘Is there, or has there ever been, any type of moisture damage (spots or 
similar) in the home?’ 
Any mold or dampness indicator—The presence of any of the three aforementioned exposure 
indicators. 
Exposure score—The sum of mold and dampness indicators (ranging from 0 to 3). 
Participants who answered ‘I don’t know’ to the above questions were coded as missing. 
 
3.3.3 Outcome assessment 
3.3.3.1 Asthma, rhinitis, rhinoconjunctivitis, and eczema 
In studies I, II, and V allergic outcomes at ages 1, 2, 4, 8, 12, and 16 years were derived based 
on parental answers from questionnaires at the different follow-up periods. In study I incident 
disease was defined as fulfilling the diagnosis of asthma, rhinitis, or eczema at the specific 
age without fulfilling it at any prior follow-up. 
In study III, allergic outcomes were also derived based on parental answers to questions at 
each cohort’s respective follow-up period, and at ages 14-16 years a combination of 
children’s and parent’s answers were utilized. Table 5 summarizes the studies outcome 
definitions. 
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Table 5. Definitions of allergic outcomes.   
Variable Definition Study 
Asthma at age one 
year 
≥3 episodes of wheeze after three months of age combined either 
with treatment with inhaled glucocorticosteroids or signs of 
suspected hyperreactivity (wheezing or severe coughing with 
exertion and cold weather, or disturbed coughing at night) without 
concurrent upper respiratory infection. 
I, II, V 
Asthma at age two 
years 
≥3 episodes of wheeze after one year of age combined with treatment 
with inhaled glucocorticosteroids or signs of suspected 
hyperreactivity (wheezing or severe coughing with exertion and cold 
weather, or disturbed coughing at night) without concurrent upper 
respiratory infection. 
I, II, V 
Asthma at ages four, 
eight, 12, and 16 
years 
≥4 episodes of wheeze in the last 12 months or ≥1 episode of wheeze 
during the same time period in combination with occasional or 
regular treatment with inhaled glucocorticosteroids. 
I, II, V 
Rhinitis at age one 
year 
Symptoms from eyes or nose after exposure to furred pets or pollen 
or doctor’s diagnosis of allergic rhinitis from the first 3 months of 
life. 
I, II, V 
Rhinitis at age two, 
four, and eight years 
Symptoms from eyes or nose after exposure to furred pets or pollen 
or doctor’s diagnosis of allergic rhinitis since the previous 
questionnaire. 
I, II, V 
Rhinitis at age 12 
years 
Symptoms from eyes or nose after exposure to furred pets or pollen 
during the last 12 months or doctor’s diagnosis of allergic rhinitis 
from the age of 10 years. 
I, II, V 
Rhinitis at age 16 
years 
Symptoms from eyes or nose after exposure to furred pets or pollen 
during the last 12 months or doctor’s diagnosis of allergic rhinitis 
from the age of 12 years. 
I, II, V 
Eczema at age one 
year 
Dry skin, itchy rashes for ≥2 weeks at specific location (face or arm 
or leg extension surfaces, or arm or leg flexures, or wrist or ankle 
flexures) of rash or doctor’s diagnosis of eczema after 3 months of 
age. 
I, II 
Eczema at age two 
years 
Dry skin, itchy rashes for ≥2 weeks at specific location (face or arm 
or leg extension surfaces, or arm or leg flexures, or wrist or ankle 
flexures) of rash or doctor’s diagnosis of eczema after 1 year of age. 
I, II 
Eczema at age four 
years 
Dry skin, itchy rashes for ≥2 weeks during the last 12 months at 
specific location (face or arm or leg extension surfaces, or arm or leg 
flexures, or wrist or ankle flexures) of rash or doctor’s diagnosis of 
eczema after 2 years of age. 
I, II 
Eczema at age eight 
years 
Dry skin, itchy rashes for ≥2 weeks during the last 12 months at 
specific location (face or arm or leg flexures, or wrists or ankles, or 
neck) of rash or doctor’s diagnosis of eczema after 7 years of age.  
I, II 
Eczema at age 12 
years 
Dry skin, itchy rashes during the last 12 months at specific location 
(arm or leg flexures, or wrists or ankles, or neck) of rash or doctor’s 
diagnosis of eczema after 10 years of age. 
I, II 
Eczema at age 16 
years 
Dry skin, itchy rashes during the last 12 months at specific location 
(arm or leg flexures, or wrists or ankles, or neck) of rash or doctor’s 
diagnosis of eczema after 12 years of age. 
I, II  
Asthma at ages 4-6 
years 
(MeDALL definition) 
Positive answer to two out of three: 
1) Doctor’s diagnosed asthma ever (parental reported);  
2) Asthma medication in the past 12 months (parental reported);  
3) Wheezing in the past 12 months (parental reported) 
III 
Asthma at ages 8-10 
years 
(MeDALL definition) 
Positive answer to two out of three: 
1) Doctor’s diagnosed asthma ever (parental reported);  
2) Asthma medication in the past 12 months (parental reported);  
3) Wheezing in the past 12 months (parental reported) 
III 
Asthma at ages 14-16 
years 
(MeDALL definition) 
Positive answer to two out of three: 
1) Doctor’s diagnosed asthma ever (parental reported);  
2) Asthma medication in the past 12 months (child reported, if 
III 
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3.3.3.2 Clinical phenotypes 
To study timing of onset, progression, and persistence of allergic diseases we classified 
asthma, rhinitis, and rhinoconjunctivitis into early-transient, persistent, and adolescent/late-
onset clinical phenotypes in studies III and V. In study III early-transient disease was defined 
as having the disease only during the age interval 4-6 years, but not after (age intervals 8-10 
and 14-16 years). Persistent disease was defined as having the disease of interest at the first 
age interval (4-6 years) and still having the disease at the latest age interval (14-16 years). 
Adolescent-onset phenotype was defined as being disease free at the first two age intervals 
(4-6 and 8-10 years) and only having the disease at the latest age interval (14-16 years).  
In study V comparable definitions were used. Asthma phenotypes were defined as: early-
transient asthma and was classified as having asthma at ages 1, 2, or 4 years but not again at 
any successive follow-ups; persistent asthma was classified as having asthma at ages 1, 2, or 
4 years and then again at ages 8, 12, or 16 years; and late-onset asthma was defined as having 
the first incidence of asthma at ages 8, 12, or 16 years.
115
 
3.3.3.3 IgE sensitization 
At ages 4, 8, and 16 years, blood sampling was performed in 2614 (64%), 2470 (60%), and 
2547 (62%) participants respectively. At each follow-up, sera were screened with Phadiatop® 
and fx5® for various inhalant and food allergens respectivly.
91
 Sera that scored positive for 
Phadiatop® or fx5® were subsequently analyzed for allergen-specific IgE antibodies. A 
technical cut-off at 0.35 kUA/l was set.  
available);  
3) Wheezing in the past 12 months and/or breathing difficulties, 
where available (child reported, if available) 
Rhinoconjunctivitis at 
ages 4-6 years 
(MeDALL definition) 
Positive answer to the following questions: 
1) In the past 12 months problems with sneezing, or a runny, or 
blocked nose when child did not have a cold or flu (parental 
reported); 
2) In the past 12 months, has this nose problem been accompanies by 
itchy-watery eyes (parental reported). 
III 
Rhinoconjunctivitis at 
ages 8-10 years 
(MeDALL definition) 
Positive answer to the following questions: 
1) In the past 12 months problems with sneezing, or a runny, or 
blocked nose when child did not have a cold or flu (parental 
reported); 
2) In the past 12 months, has this nose problem been accompanies by 
itchy-watery eyes (parental reported). 
III 
Rhinoconjunctivitis at 
ages 14-16 years 
(MeDALL definition) 
Positive answer to the following questions: 
1) In the past 12 months problems with sneezing, or a runny, or 
blocked nose when child did not have a cold or flu (child reported, if 
available); 
2) In the past 12 months, has this nose problem been accompanies by 
itchy-watery eyes (child reported, if available). 
III 
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Any allergen sensitization was defined as a positive reaction to any of the tested allergens. 
Inhalant allergens were classified as either indoor (cat, dog, horse, and/or house dust mite) or 
outdoor (timothy grass, birch, mugwort, and/or mold).
91
 Food allergen sensitization was 
defined as sensitization to any tested food allergen (cow’s milk, hen’s egg, soybean, peanut, 
cod fish or wheat). In studies II and V to explore the effect of exposure (SHS or 
mold/dampness) on sensitization combined with symptoms we characterized allergic vs non-
allergic phenotypes by combining symptoms of asthma, rhinitis, and eczema with and 
without sensitization.   
3.3.3.4 Lung function 
Lung function testing was performed in 2605 participants (spirometry or impulse 
oscillometry) at age 16 years. Indices of pulmonary function were analyzed by spirometry 
and by IOS using the Jaeger MasterScreen-IOS system (Carefusion Technologies, San Diego, 
CA) and have been described in depth elsewhere.
147
 For spirometry indices, multiple 
maximal expiratory flow volume measurements were performed by each participant and the 
highest values of FEV1, and FVC were used in analyses.
148
 The FEV1/FVC ratios were 
expressed as percentages. Standard deviation scores for FEV1, FVC, and FEV1/FVC were 
computed taking age, sex, height, and ethnicity into account using the Global Lung Function 
Initiative (GLI) reference values.
149
 The spirometer was calibrated daily using a 3-Liter 
precision syringe.  
Further information on the IOS system has also been given in detail elsewhere.
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 In 
study V, IOS indices were assessed by having participants perform tidal breathing through a 
mouthpiece while pressure impulses were delivered from a loud speaker throughout the 
respiratory tract.
148
 Each participant performed the maneuver at least twice and quality 
control checks were conducted by visual examination of waveforms at the time of the 
maneuver.
150
 The mean value of resistance at 5 Hertz (Hz) (R5), resistance at 20 Hz (R20), 
frequency dependence of resistance (R5-20), and the square root of the area of reactance 
(AX
0.5
) were used in the final analyses. Daily accuracy checks for the IOS system were 
conducted using a reference resistance (0.20 kPa·L
−1
·s
−1
).
150
 
Fractional exhaled nitric oxide (FeNO) is a simple noninvasive test which reflects 
eosinophilic airway inflammation.
152
 We used an Eco Medic instrument system (ECO 
MEDICS AG, Dürnten, Switzerland) and single breath technique was used according to the 
ATS and ERS guidelines.
153
 FeNO was expressed as parts per billion (ppb). 
 
3.4 STATISTICAL ANALYSES 
The majority of statistical analyses were performed with STATA (release 12; Stata Corp., 
College Station, TX, USA). In study III R, version 3.2.2 (R Core Team, 2012) was also used. 
3.4.1 Prevalence and incidence 
We used prevalence and incidence to summarize the frequency of exposure, outcomes, and 
sociodemographic characteristics in our study populations. Prevalence and incidence were 
presented as frequency or percent of total.   
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3.4.2 Chi square test 
The chi square test, also written as X
2
, is used to determine whether there are significant 
differences between expected frequencies and the observed frequencies between categorical 
variables. In the context of this thesis the chi square test was used to compare the complete 
baseline cohort with selected study populations with regards to sociodemographic 
characteristics and potential confounding factors.  
3.4.3 Logistic regression 
Logistic regression is a statistical method used to assess associations between two variables 
when the dependent variable (outcome) is binary. In general, logistic regression was used in 
studies I-V to identify potential confounding factors by conducting stepwise logistic 
regression. In studies I, II, III, and V final covariates were selected if they lead to more than 
5% change in odds ratio (OR) or were selected based on putative risk factors. In study IV, 
covariates were selected if they changed the β coefficient by 10% and likelihood ratios test 
was significantly different (p-value <0.05) from a simpler model. The magnitude of 
associations are represented as odds ratios (OR) with corresponding 95% confidence intervals 
(CI).  
In study I final covariates included sex, parental history of allergic disease, and 
socioeconomic status. In some analyses we also adjusted for parental smoking throughout 
childhood which was conducted to account for any SHS after infancy. Furthermore, we tested 
if there was any effect modification by sex or allergic heredity with exposure to maternal 
smoking during pregnancy or parental smoking during infancy by including interaction terms.  
Study II included parental history of allergic disease and socioeconomic status as final 
covariates. As with study I we also adjusted some models for SHS throughout childhood. We 
tested if there was any significant interaction between SHS in infancy and parental allergic 
disease. Additionally, we stratified by maternal smoking during pregnancy.  
In study III, sex, parental history of allergic disease, parental educational level, older siblings, 
study centers (GINIplus, LISAplus, and PIAMA), and intervention versus observational 
study arms (GINIplus and PIAMA) were selected based on subject-matter knowledge and 
covariates selected based on model testing included daycare attendance and breastfeeding. To 
separate the effects of maternal smoking during pregnancy from other postnatal SHS 
exposure, in some models we adjusted for SHS throughout childhood (age intervals 1-2, 4-6, 
8-10, and 14-16 years).  
Confounders selected in study IV included age, sex, and height and were selected using a 
stepwise linear regression model. We also tested a mutually adjusted model which included 
smoking during pregnancy, SHS during infancy, SHS exposure at age 16 years, and 
adolescent smoking at age 16 years to assess any independent effects. Furthermore, we 
stratified our analyses by sex and by wheeze in the last 12 months.   
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The final covariates included in study V consisted of sex, socioeconomic status, parental 
history of allergic disease, maternal smoking during pregnancy, parental smoking during 
infancy, maternal age, and older siblings. We also stratified our analyses by building 
construction period due to various building materials and techniques utilized at different time 
periods. 
3.4.4 Multinomial logistic regression  
Multinomial logistic regression is a statistical method similar to logistic regression, but 
instead of having a binary dependent variable this model can predict the probabilities of 
different possible outcomes of a categorically distributed dependent variable. Multinomial 
logistic regression was used in studies II, III, and V.  
3.4.5 Generalized estimating equations (GEE) 
Used in studies I, II, III, and V, GEE modeling was the most prevalent statistical method used 
in this thesis. GEE models are a type of mixed model that are used in the analysis of 
longitudinal data.
154
 We used an unstructured correlation matrix, and in studies I and II an 
interaction term with time was included to assess the effect of exposure over time.  
3.4.6 Meta-analysis 
Random effects meta-analysis is a statistical method which is used to combine effect 
estimates from different studies, and in the case of study III effect estimates from cohort 
specific GEE analyses. One can combine estimates using fixed or random effects. A fixed-
effect meta-analysis estimates a single effect that is assumed to be common to every study, 
whereas random-effect meta-analysis estimates the mean of a distribution of effects and takes 
into account within-cohort and between-cohort variation.
155
  
3.4.7 Linear regression and quantile regression 
Linear regression is a statistical approach used to assess the association between a continuous 
dependent variable with an independent variable (exposure). Quantile regression, sometimes 
referred to as regression on the median, is used when data are skewed and is robust to 
outliers. Both linear and quantile regression were used in study IV.  
 
3.5 ETHICAL APPROVAL 
The BAMSE project was approved by the regional ethics committee at Karolinska Institutet, 
Stockholm, Sweden (reference numbers – 93:189; 98:175; 02:420; and 2007/1634-31).  
The birth cohorts included in study III have also been approved by their respective ethical 
review boards.  
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Figure 5. Prevalence of tobacco smoke exposure in BAMSE. 
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4 RESULTS 
4.1 PREVALENCE OF TOBACCO SMOKE EXPOSURE IN BAMSE 
In BAMSE the prevalence of maternal smoking during pregnancy was 12.7% and parental 
smoking during infancy was somewhat higher at 20.8%. Figure 5 presents the prevalence of 
exposure to tobacco smoking during pregnancy to age 16 years in BAMSE. Parental smoking 
slowly declined from around 20% at birth to 14% at age 16 years. Figure 6 illustrates the overlap 
between maternal smoking during pregnancy and parental smoking during infancy. In BAMSE 
paternal smoking habits were not queried at baseline, however this question was asked at the 12 
year follow-up and 17% (n=566) indicated they smoked during the mothers’ pregnancy.  
At age 16 years 280 (12.2%) of adolescents were smoking, 102 (4.4% of the study population) 
smoked daily and 178 (7.8% of the study population) smoked occasionally. The mean age of 
smoking onset (≥1 cigarette/week) was age 14.7 years. The prevalence of smoking was 
comparable between males and females. However, of the 102 (4.4%) participants who used 
smokeless tobacco (snus/moist snuff) only five were females. Nearly two thirds of those who 
used smokeless tobacco were also active smokers. Saliva cotinine concentrations were higher 
among males than females (geometric mean 0.21 ng/ml versus 0.13 ng/ml), and is likely explained 
by the higher smokeless tobacco use among males. 
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Figure 7. Prevalence of tobacco smoke exposure in MeDALL. 
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4.2 PREVALENCE OF TOBACCO SMOKE EXPOSURE IN MEDALL 
The prevalence of maternal smoking during pregnancy ranged from 12-20%, and exposure to 
SHS during infancy ranged from 16-43% across the cohorts included in study III (Figure 7). The 
prevalences of SHS exposure from ages 1-16 years are also presented in Figure 7 below. 
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Maternal smoking 
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154 (3.8%) 
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Figure 6. The overlap between tobacco smoke exposure during pregnancy and infancy in BAMSE. 
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Figure 8. Prevalence of allergic diseases in BAMSE. 
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4.3 PREVALENCE OF ALLERGIC DISEASES AND SENSITIZATION 
4.3.1 Prevalence of allergic diseases in BAMSE 
The prevalences of asthma, rhinitis, and eczema in BAMSE are presented in Figure 8. Over ages 
1 to 16 years asthma averaged around 6%, while rhinitis became increasingly more prevalent as 
children became older, and by age 16 years 25.4% had rhinitis. Eczema was more common in 
pre-school ages but tended to decline as participants became older, and at age 16 years 9.8% had 
eczema.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2 Prevalence of sensitization in BAMSE 
The prevalence of sensitization to any allergen at ages 4, 8, and 16 years were 24.1%, 34.8%, 
and 45.9% respectively, and the overlap between any sensitization at these ages is illustrated in 
Figure 1, Manuscript II. Sensitization became more prevalent and few children lost their 
sensitization.  In addition, Figures 9 and 10 illustrate the overlap of sensitization to inhalant 
allergens and food allergens at ages 4, 8, and 16 years respectively. In general, inhalant allergen 
sensitization became increasingly more prevalent, whereas participants tended to lose their food 
allergen sensitization. 
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Figure 10. Proportional relationship of sensitization to food allergens at ages 4, 8, and 16 years 
among participants in BAMSE. 
Figure 9. Proportional relationship of sensitization to inhalant allergens at ages 4, 8, and 16 
years among participants in BAMSE. 
8 years 
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4.3.3 Prevalence of allergic diseases in MeDALL 
The prevalence of asthma and rhinoconjunctivitis varied across the cohorts included in study III. 
BAMSE consistently had the highest prevalence of asthma and the German cohorts (GINIplus, 
LISAplus, and MAS) had higher prevalences of rhinoconjunctivitis (Figure 11), but in all 
cohorts rhinoconjunctivitis increased with age. The prevalence of asthma phenotypes were 
similar at around 4%, and the prevalence of rhinoconjunctivitis phenotypes were highest for 
adolescent-onset (12.2%) and lowest for early-transient (1.6%).  
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4.4 LUNG FUNCTION SUMMARY STATISTICS 
Table 6 below summarizes the anthropometric and lung function characteristics of participants 
with lung function data at age 16 years. Generally, males had larger lung volumes than females, 
as expected, but had lower airway resistance.  
 
 
 
 
4.5 MATERNAL SMOKING DURING PREGNANCY IN RELATION TO ALLERGIC 
DISEASES AND LUNG FUNCTION 
4.5.1 Allergic diseases 
In studies I and III we observed consistent associations between maternal smoking during 
pregnancy and asthma up to adolescence. In study I we found that children exposed to maternal 
smoking during pregnancy had increased overall risk of asthma up to age 16 years (OR = 1.45; 
95% CI, 1.15–1.83) (Figure 12). Moreover, following adjustment for parental smoking 
throughout childhood, the risk of prevalent and incident asthma remained elevated (see 
manuscript I, Table 2). Likewise in study III, results from meta-analyses also suggested 
increased risk of asthma up to ages 14-16 years (OR = 1.19; 95% CI, 0.98-1.43) (Figure 13). 
More specifically, in study III we observed increased risk of early-transient asthma (OR = 1.71; 
95% CI, 1.21-2.41), which is in line with study I where the highest risks of asthma were seen in 
early childhood.  
Table 6. Anthropometric and lung function characteristics among children at age 16 years in 
BAMSE. 
 16 years 
Variable Males Females 
 N
* 
Mean SD N
* 
Mean SD 
Age, years 1092 16.7 0.4 1203 16.7 0.4 
Height, meters 1092 1.8 0.07 1203 1.7 0.06 
FEV1, milliliters 1052 4501.8 644.5 1175 3484.9 443.6 
FEV1, z-score 1051 -0.03 0.96 1175 -0.04 0.90 
FVC, milliliters 969 5382.7 778.6 1140 4037.6 526.0 
FVC, z-score 968 0.15 0.95 1140 0.15 0.88 
FEV1/FVC, % 929 83.8 6.6 1112 86.5 6.1 
FEV1/FVC, z-score 929 -0.30 0.98 1112 -0.36 0.95 
Saliva cotinine level (ng/ml)
|| 
706 0.21 10.0 817 0.13 7.0 
Impulse oscillometry N
* 
Median IQR N
*
 Median IQR 
R5, (Pa*L
-1
)*s 1051 325.0 95.0 1143 400.0 100.0 
R20, (Pa*L
-1
)*s 1051 310.0 75.0 1143 375.0 85.0 
R5-R20, (Pa*L
-1
)*s 1051 15.0 45.0 1143 20.0 55.0 
AX
0.5
, (Pa*L
-1
) 1050 160.0 130.0 1143 270.0 195.0 
FeNO (ppb) 1081 16.0 14.1 1188 12.8 10.4 
* 
Total number of subjects. 
|| 
Geometric mean. 
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NOTE: Weights are from random effects analysis
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Figure 12. Association between maternal smoking during pregnancy in relation to asthma, rhinitis, 
and eczema during childhood and adolescence in BAMSE. Adjusted for sex, parental allergic 
disease, and socioeconomic status. ○ Asthma; ● Rhinitis; ● Eczema. 
 
Figure 13. Associations between maternal smoking during pregnancy and prevalent asthma up to 
14 to 16 years of age in MeDALL. Cohort specific ORs and 95% CIs were obtained by GEE 
adjusted for sex, parental education level, parental allergy, older siblings, breastfeeding, study 
center, intervention arm, and early day-care attendance.  
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A significant dose-response relationship for increasing number of cigarettes smoked during 
pregnancy and risk of asthma was seen in study I, and children exposed to ≥10 cigarettes per day 
during any trimester of pregnancy had increased risk for asthma up to age 16 years (OR = 1.68; 
95% CI, 1.23-2.29). Similarly, in study III children exposed to high doses of maternal smoking 
during pregnancy (≥10 cigarettes/day) had significantly increased risks of both early-transient 
asthma and persistent asthma (OR = 2.07; 95% CI, 1.60-2.68 and OR = 1.66; 95% CI, 1.29-2.15, 
respectively). Additionally, in study III we also observed evidence for persistent 
rhinoconjunctivitis among participants exposed to maternal smoking during pregnancy (OR = 
1.77; 95% CI, 1.20-2.59).  
No consistent associations between maternal smoking during pregnancy and IgE sensitization, 
rhinitis, or eczema were observed in studies I and II.  
4.5.2 Lung function 
In study IV, participants exposed to maternal smoking during pregnancy had significantly 
reduced FEV1/FVC ratios at age 16 years (-1.1% (95% CI, -2.0 to -0.2)). This reduction in 
FEV1/FVC ratios remained after mutually adjusting for adolescent smoking, SHS during 
infancy, and SHS smoke at age 16 years (-1.0% (95% CI, -2.1 to 0.02)), albeit not statistically 
significant. Indices from IOS suggested increased airway resistance among individuals exposed 
to maternal smoking during pregnancy. Compared to unexposed participants, those exposed to 
maternal smoking during pregnancy had significant increases in R5 (13.1 Pa·L
–1
·s (95% CI, 1.4 
to 24.9)), R5-20 (9.2 Pa·L
–1
·s (95% CI, 2.8 to 15.6)), and AX
0.5
 (21.8 (Pa·L
–1
·s)
0.5
 (95% CI, 3.9 to 
39.7)) at age 16 years. 
 
4.6 SHS EXPOSURE AND ALLERGIC DISEASES 
4.6.1 Allergic diseases 
In studies I and III we explored the association between exposure to SHS during infancy with 
asthma, rhinitis, rhinoconjunctivitis, and eczema. In BAMSE, exposure to parental smoking 
during infancy was associated with an overall increased risks of asthma (OR = 1.23; 95% CI, 
1.01-1.51), rhinitis (OR = 1.18; 95% CI, 1.01-1.39), and eczema (OR = 1.26; 95% CI, 1.09-1.45) 
up to age 16 years (Figure 14). Similarly, in study III we observed combined elevated risks of 
overall asthma among participants exposed to SHS during infancy (OR = 1.15; 95% CI, 1.00- 
1.31). However, due to the high correlation between maternal smoking during pregnancy and 
SHS exposure during infancy, in sensitivity analyses we attempted to disentangle these 
exposures. Because we had increased numbers in study III, we categorized exposure into 
maternal smoking during pregnancy only, parental smoking during infancy only, and exposure 
to both. We found evidence suggesting that the association between SHS exposure during 
infancy and asthma risk was mainly driven by exposure during pregnancy (Figure 15).  
In study III SHS exposure during infancy was not associated with overall risk of 
rhinoconjunctivitis up to adolescence (OR = 1.05; 95% CI, 0.92-1.19), nor was SHS during 
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infancy associated with phenotypes of asthma or rhinoconjunctivitis. We also examined whether 
exposure to SHS during different periods of childhood (infancy, 1-2, 4-6, 8-10, or 14-16 years) 
was associated with the risk of adolescent-onset asthma and rhinoconjunctivitis, but following 
adjustment for maternal smoking during pregnancy, no significant associations were apparent. 
 
 
 
 
 
 
 
 
  
Figure 14. Associations between SHS exposure during infancy in relation to asthma, rhinitis, and 
eczema during childhood and adolescence in BAMSE. Adjusted for sex, parental allergic disease, and 
socioeconomic status. ○ Asthma; ● Rhinitis; ● Eczema. 
 
Figure 15. Associations between maternal smoking during pregnancy only, SHS exposure during 
infancy only, and both in relation to asthma and rhinoconjunctivitis up to age 14-16 in MeDALL.  
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4.6.2 IgE sensitization 
In study II we evaluated the association between tobacco smoke exposure and the development 
of sensitization. Participants exposed exclusively to SHS exposure during infancy had increased 
risk of food allergen sensitization at age four years (OR = 1.47; 95% CI, 1.08-2.00), and 
nonsignificantly increased risks at ages eight (OR = 1.34; 95% CI, 0.99-1.79) and 16 years (OR 
= 1.32; 95% CI, 0.93-1.86). At age four years there was an increased risk of indoor allergen 
sensitization among participants exposed exclusively to SHS exposure during infancy (OR = 
1.50; 95% CI, 1.00-2.24), but was not apparent at later ages.  
In longitudinal analyses, we found that participants exposed during infancy had a borderline 
overall increased risk of food allergen sensitization up to age 16 years (OR = 1.24; 95% CI, 
0.98-1.56) (Figure 16). At ages 4, 8, and 16 years there was a tendency for increased risks for 
food allergen sensitization. In analyses of single allergens we observed positive associations for 
all food allergens with the exception of cod fish (see Manuscript II, Table 2). In addition, dose 
response analyses indicated that children exposed to ≥10 cigarettes per day had increased risk of 
food allergen sensitization (see Manuscript II, Table 3).  
 
 
 
 
 
 
 
  
Figure 16. Association between exposure to SHS during infancy and the risk of allergic sensitization 
during the first 16 years of life in BAMSE. 
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We were curious to see if this association was only present for participants with allergic 
heredity, so we stratified our findings by those with and without parental history of allergic 
disease. We found no statistically significant differences between those participants with (OR = 
1.36; 95% CI, 0.90-2.06) and without (OR = 1.17; 95% CI, 0.88-1.57) allergic parents.  
Being sensitized does not necessarily mean you present with symptoms of allergic disease. 
Therefore, we combined any sensitization and food allergen sensitization with symptoms of 
asthma, rhinitis, and eczema (Figure 17). In these analyses we observed no associations with 
exposure to SHS during infancy and asthma with or without sensitization. However, we 
observed an increased risk for rhinitis among nonsensitized participants (OR = 1.53; 95% CI, 
1.01-2.31) and an overall increased risk of eczema in those participants with any sensitization 
(OR = 1.62; 95% CI, 1.20-2.18).    
 
 
 
  
Figure 17. Association between SHS exposure during infancy and the risk of any or food allergen sensitization 
and allergic diseases in BAMSE. 
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4.7 ADOLESCENT SMOKING IN RELATION TO LUNG FUNCTION AT AGE 16 
YEARS  
4.7.1 Adolescent smoking and lung function at age 16 years 
The association between adolescent smoking and lung function are presented in Table 7. 
Compared with non-smokers, participants who indicated they smoked daily or occasionally had 
reduced FEV1/FVC ratios at age 16 years (-0.9% (95% CI, -1.8 to -0.1)). In a model combining 
maternal smoking during pregnancy, SHS during infancy, SHS exposure at 16 years, and 
adolescent smoking, FEV1/FVC ratios were non-significantly lower among adolescent smokers 
at age 16 years (-0.8% (95% CI, -1.7 to 0.1)). Using indices from IOS we found that adolescent 
smoking was associated with a significant increase in R5-20 (6.5 Pa·L–1·s (95% CI, 0.7 to 12.2)) 
at age 16 years, which is indicative of increased airway resistance in the peripheral airways. 
However, no associations were seen for R5, R20, or AX
0.5
.  
 
 
4.7.2 Saliva cotinine levels and lung function 
When we excluded smokeless tobacco users and used a cut-off of ≥12 ng/ml to discriminate 
adolescent smokers from non-smokers, we correctly classified 97.6% of daily smokers. Our 
finding of a lower FEV1/FVC ratios among active smokers was corroborated when using this 
cut-off. We observed a decline in FEV1/FVC ratios of -1.5% (95% CI, -2.5 to -0.4) compared to 
children with a saliva cotinine concentration of <12 ng/ml.   
  
Table 7. Differences in lung function between exposed and unexposed participants to tobacco smoke and 
lung function at age 16 years in BAMSE. 
  FEV1 (ml) FVC (ml) FEV1/FVC (%) 
 n Diff.
* 
95% CI Diff.
* 
95% CI Diff.
* 
95% CI 
Participants smoking    
Non-smokers 2015 Reference Reference Reference 
Adolescent smoking
†
 280 -12.6 -69.3;44.2 16.6 -50.1;83.3 -0.9 -1.8;-0.1 
Occasional smokers 178 -34.4 -103.6;34.8 17.2 -64.1;98.4 -1.1 -2.1;-0.04 
Daily smokers 102 26.3 -64.3;116.9 15.6 -91.2;122.3 -0.7 -2.1;0.6 
*
 Calculated by linear regression on the mean adjusted for sex, age, and height. 
† 
Daily or occasional smoking. 
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Unexposed 
2215 (74.2%) 
4.8 MOLD AND DAMPNESS EXPOSURE AND ALLERGIC DISEASES 
4.8.1 Asthma, rhinitis, and sensitization 
In study V we examined if indoor dampness or mold was associated with increased risk of 
asthma, rhinitis, and sensitization in childhood or adolescence.  
Using questionnaires from baseline (two months) we ascertained how many participants were 
exposed to mold odor, visible mold, or dampness damage. Of the 3798 included participants, 
299 (9.1%) were exposed to mold odor, 325 (8.6%) to visible mold, 758 (23.5%) to dampness 
damage, and 967 (30.4%) to any mold or dampness indicator at baseline. Figure 18 below 
illustrates the overlap between these exposures.  
 
 
 
 
 
 
 
 
 
 
 
 
  
110 (3.8%) 
Mold odor 
48 (1.6%) 
20 (0.7%) 
81 (2.7%) 
76 (2.5%) 
Visible mold 
67 (2.2%) 
Dampness damage 
366 (12.3%) 
Figure 18. Distribution and proportional relationship of mold odor, visible mold, and dampness 
damage exposure at baseline in BAMSE (n=2983). 
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In longitudinal analyses from birth to age 16 years, participants exposed to mold odor, visible 
mold, or dampness damage during infancy had an overall increased risk of asthma (Figure 19). 
An increased risk was seen for rhinitis, but only in participants exposed to mold odor (OR = 
1.29; 95% CI, 1.03-1.62) or visible mold (OR = 1.28; 95% CI, 1.04-1.58).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Participants exposed to an increasing number of mold or dampness indicators (exposure score) 
showed a significant trend for increased odds of asthma (ptrend=0.002) (Table 8). And a similar, 
however non-significant trend was observed for rhinitis (ptrend=0.14). 
No overall or dose dependent associations with indicators of mold or dampness during infancy 
and IgE sensitization to airborne or food allergens were observed. However, an increased risk 
for non-allergic asthma (OR = 1.80; 95% CI, 1.27–2.55) and non-allergic rhinitis (OR = 1.41; 
95% CI, 1.03–1.93) were observed in participants exposed to any mold or dampness indicator 
during infancy.   
Interestingly, we observed somewhat higher risks of rhinitis in participants living in homes built 
after 1975 compared with those homes constructed before 1961 (Table 4, manuscript V). This 
could have to do with building construction practices and materials during various periods, as oil 
prices increased in 1974, and a focus on energy efficiency became increasingly important.
156
 For 
example, the introduction of self-leveling mortar from 1977 to 1983 has since shown to emit 
chemicals such as ammonia and sulfhydryl compounds in the presence of moisture.
115 117
 
However, we observed no significant interaction between exposure to mold or dampness 
indicators and asthma or rhinitis.   
Figure 19. Associations between exposure to mold or dampness during infancy and the risk of 
asthma, rhinitis, eczema, aero-allergen or food allergen sensitization up to age 16 years in BAMSE. 
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Table 8. Severity of exposure to mold or dampness indicators
*
 in relation to 
overall asthma, rhinitis, and sensitization among children in BAMSE. 
 Exposure score 
(crude model
†
) 
Exposure score 
(adjusted model
‡
) 
 OR (95% CI) OR (95% CI) 
Asthma 
No mold or dampness indicator Reference Reference 
1 indicator 1.24 (1.00-1.55) 1.16 (0.93-1.44) 
2 indicators 1.47 (1.09-2.00) 1.37 (1.01-1.86) 
3 indicators 2.00 (1.26-3.16) 1.73 (1.10-2.74) 
p-value for trend <0.01 <0.01 
Rhinitis 
No mold or dampness indicator Reference Reference 
1 indicator 1.09 (1.02-1.21) 1.03 (0.87-1.22) 
2 indicators 1.24 (0.97-1.59) 1.18 (0.92-1.52) 
3 indicators 1.43 (0.96-2.13) 1.23 (0.82-1.85) 
p-value for trend 0.01 0.14 
Aeroallergen sensitization
§
 
No mold or dampness indicator Reference Reference 
1 indicator 0.94 (0.78-1.14) 0.94 (0.77-1.13) 
2 indicators 0.83 (0.62-1.11) 0.85 (0.63-1.14) 
3 indicators 1.01 (0.63-1.62) 0.90 (0.55-1.48) 
p-value for trend 0.30 0.23 
Food allergen sensitization
¶ 
No mold or dampness indicator Reference Reference 
1 indicator 0.87 (0.70-1.09) 0.87 (0.69-1.09) 
2 indicators 0.99 (0.71-1.38) 1.02 (0.73-1.42) 
3 indicators 1.33 (0.80-2.22) 1.22 (0.72-2.07) 
p-value for trend 0.93 0.99 
* 
Mold odor, visible mold, or dampness damage. 
† 
Crude odds ratio (OR) and 95% confidence intervals (CI) obtained from GEE.  
‡
 Odds ratio (OR) and 95% confidence intervals (CI) obtained from GEE adjusted 
for  sex, socioeconomic status, parental allergic disease, maternal smoking during 
pregnancy, parental smoking during infancy, maternal age <26 years, and presence 
of siblings. 
§
 Sensitization to cat, dog, horse, mite, timothy, birch, mugwort, or mold. 
¶
 Sensitization to cow’s milk, hen’s egg, soybean, peanut, cod fish, or wheat. 
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4.8.2 Phenotypes of asthma 
We found that participants exposed to any mold or dampness indicator during infancy had an 
increased risk of persistent asthma (OR = 1.73; 95% CI, 1.20-2.50). Similar results were seen for 
mold odor, visible mold, and dampness damage separately (Figure 20). Exposure to dampness 
damage was also significantly associated with an increased risk of late-onset asthma (OR = 1.41; 
95% CI, 1.02-1.95).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 20. Exposure to mold or dampness indicators during infancy and early-transient, persistent, 
and late-onset asthma in BAMSE. 
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4.9 ADDITIONAL RESULTS 
4.9.1 Paternal smoking during pregnancy and allergic diseases 
There is literature supporting an association between paternal smoking during pregnancy (i.e. 
maternal SHS exposure during pregnancy) and asthma in children
40 157
, and such data were 
collected at the 12 year follow-up in BAMSE. In explorative analyses we found that exposure to 
paternal smoking during pregnancy was associated with asthma up to age 16 years even among 
those unexposed to maternal smoking during pregnancy (OR = 1.39; 95% CI, 1.07-1.80) (Table 
9). Similarly, in a mutually adjusted model we observed an overall increased risk of asthma up 
to age 16 years in participants exposed to paternal smoking during pregnancy (Table 10). We 
observed no association between exposure to paternal smoking during pregnancy and rhinitis. 
An increased risk of eczema among participants exposed to paternal smoking during pregnancy 
and eczema was seen, however this disappeared following adjustment for parental smoking 
during infancy.   
Table 9. Overall associations between paternal smoking during pregnancy and allergic diseases 
and sensitization stratified by maternal smoking during pregnancy (BAMSE). 
 No maternal smoking 
during pregnancy 
Yes maternal smoking 
during pregnancy 
Paternal smoking during pregnancy OR (95% CI) OR (95% CI) 
   Asthma
*
 1.39 (1.07-1.80) 1.15 (0.72-1.83) 
   Rhinitis
*
 1.15 (0.94-1.42) 1.19 (0.81-1.75) 
   Eczema
*
 1.25 (1.03-1.50) 1.00 (0.70-1.44) 
   IgE sensitization
† 
    Any allergen
‡
 0.89 (0.67-1.18) 1.15 (0.75-1.79) 
    Inhalant allergens
||
 0.91 (0.67-1.23) 1.35 (0.84-2.19) 
    Food allergens
¶
 1.02 (0.73-1.44) 0.96 (0.55-1.68) 
*
 OR and 95% CIs obtain from GEE adjusted for adjusted for sex, parental allergic disease, and 
socioeconomic status. 
†
 OR and 95% CIs obtain from GEE adjusted for adjusted for sex, parental allergic disease, SHS 
exposure during infancy, and socioeconomic status. 
‡
 Any inhalant and/or food allergen sensitization. 
||
 Sensitization to cat, dog, horse, mite, timothy, birch, mugwort, or mold. 
¶
 Sensitization to cow’s milk, hen’s egg, soybean, peanut, cod fish, or wheat. 
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Table 10. Overall associations between maternal and paternal smoking during pregnancy and 
allergic diseases and sensitization in a mutually adjusted model (BAMSE). 
Paternal smoking during pregnancy* OR (95% CI) 
   Asthma
*
 1.33 (1.05-1.67) 
   Rhinitis
*
 1.16 (0.97-1.39) 
   Eczema
*
 1.19 (1.01-1.41) 
   IgE sensitization
†
  
     Any allergen
‡
 0.98 (0.78-1.24) 
     Inhalant allergens
||
 1.04 (0.80-1.33) 
     Food allergens
¶
 1.03 (0.77-1.37) 
Maternal smoking during pregnancy** 
   Asthma
**
 1.32 (1.03-1.72) 
   Rhinitis
**
 0.92 (0.74-1.14) 
   Eczema
**
 1.06 (0.87-1.29) 
   IgE sensitization
††
  
     Any allergen
‡
 0.95 (0.75-1.21) 
     Inhalant allergens
||
 0.94 (0.73-1.22) 
     Food allergens
¶
 0.93 (0.69-1.24) 
*
 OR and 95% CIs obtain from GEE adjusted for adjusted for sex, maternal smoking during 
pregnancy, parental allergic disease, and socioeconomic status. 
†
 OR and 95% CIs obtain from GEE adjusted for adjusted for sex, parental allergic disease, 
maternal smoking during pregnancy, SHS exposure during infancy, and socioeconomic status. 
‡
 Any inhalant and/or food allergen sensitization. 
||
 Sensitization to cat, dog, horse, mite, timothy, birch, mugwort, or mold. 
¶
 Sensitization to cow’s milk, hen’s egg, soybean, peanut, cod fish, or wheat. 
**
 OR and 95% CIs obtain from GEE adjusted for adjusted for sex, paternal smoking during 
pregnancy, parental allergic disease, and socioeconomic status. 
†† 
OR and 95% CIs obtain from GEE adjusted for adjusted for sex, parental allergic disease, 
paternal smoking during pregnancy, SHS exposure during infancy, and socioeconomic status. 
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5 DISCUSSION 
5.1 STRENGTHS AND LIMITATIONS 
Every epidemiological study has strengths and limitations. The most noteworthy strength of 
the materials used in this thesis is the use of prospective birth cohorts. Data collected in a 
prospective manner prevents many pitfalls which affect epidemiological studies. When 
prospectively collecting data on exposure prior to an outcome you can be relatively certain 
that exposure occurred prior to disease onset and that disease status did not influence 
reporting of exposure, however this is not necessarily the case for allergic diseases. Another 
noteworthy strength is the number of individuals included in the BAMSE cohort and pooled 
data from other birth cohorts. A large sample size allowed the analysis of subgroups and 
various disease phenotypes. Loss to follow-up, also known as drop-out, is comparably low in 
BAMSE which retained 78% of the original cohort at the 16 year follow-up.  
The majority of the data in these studies were collected via questionnaire which has the 
potential for error and is the main limitation in this thesis. This is expanded on later (section 
5.2.2).  
5.2 METHODOLOGICAL CONSIDERATIONS 
With all epidemiological studies it is critical to consider whether observed findings are 
precise, valid, and generalizable. Two major pitfalls in epidemiologic research that threaten a 
study’s validity are bias and confounding. Bias can be divided into random and systematic 
error. Systematic error can occur in the design, measurement of the exposure, measurement 
of the outcome, or in the selection or follow-up of participants.
158
 Validity is the lack of 
systematic error, and can be divided into internal validity and external validity 
(generalizability). Internal validly refers to the legitimacy of inferences made to the source 
population, and external validity pertains to the validity of the inferences made to people 
outside that population.
159
 More of external validity below (section 5.2.5).  
5.2.1 Systematic error – selection bias 
Selection bias can occur during the recruitment of study participants and/or the follow-up of 
these participants. Selection bias arises if study participants are more or less likely to be 
selected due to factors related to exposure, outcome, or both.
158
 At the recruitment stage for 
BAMSE, 75% of all eligible children were included. The survey assessing non-responders 
found that parental tobacco smoking was more prevalent among non-responders compared to 
the 75% included in BAMSE, but no other significant differences in background 
characteristics concerning known risk factors for allergy-related disease were obsereved.
134
 A 
low recruitment rate does not necessary impact the association between exposure and disease, 
but has more influence on external validity (see section 5.2.5). 
In study III, participation rates varied across included cohorts and not all cohorts provided 
data on nonparticipants. By design, PIAMA and MAS were risk-enriched, and these cohorts 
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purposely included more children with higher allergy risk. In GINIplus no differences with 
regards to socioeconomic status or parental history of allergic diseases between 
nonparticipants and the final cohort were reported.
160
  
Loss to follow-up is bias occurring during the follow-up of study participants. Response rates 
in BAMSE have been consistently high, with 78% of study participants completing 
questionnaires at age 16 years. To assess if selection bias occurred due to loss to follow-up, in 
each study we compared the selected study populations with the original participants in 
relation to background characteristics and outcomes. In general, the selected study 
populations were comparable regarding distribution of background characteristics. In study 
III participation rates varied, and at ages 14-16 years participation rates ranged from 42.6% 
(MAS) to 76.1% (BAMSE). Overall, nonsmoking parents with higher education were more 
likely to participate up to age 14 to 16 years. It is crucial to limit loss to follow up in 
prospective cohort studies, as this can bias associations between exposure and outcome and 
impact the validity of the study.  
5.2.2 Systematic error – information bias (misclassification)  
Information bias or misclassification occurs when the measurement of exposure or outcome 
in participants is erroneous. Misclassification can be either differential or nondifferential. 
Differential misclassification occurs when the classification error depends on the values of 
other variables and nondifferential misclassification is classification error that does not 
depend on the values of other variables.
159
 
All exposure and outcome information in this thesis were based on answers from parental 
and/or participant questionnaires, except for studies II and IV, which used IgE levels based 
on blood samples or lung function, respectively. Therefore, misclassification of exposure or 
outcome to some degree is unavoidable.  
Misclassification of tobacco smoking is possible due to underreporting. The negative health 
effects of tobacco smoking are well known, thus underreporting is possible in studies I-IV. 
Nevertheless, validation studies have found that self-reported data are often comparable with 
cord blood, urinary cotinine, or indoor air nicotine measurements.
161-163
 Due to the nature of 
prospective birth cohort studies, the collection of exposure information prior to disease onset 
reduces the risk of differential misclassification. In other words, parents are not influenced by 
the disease status of their child at the time of reporting, at least for exposures like maternal 
smoking during pregnancy or in the first year of life. In general, misclassification due to 
underreporting can potentially result in an underestimation of the true effect.  
In study IV we used self-reported smoking habits and smokeless tobacco use among 16 year 
old participants as well as saliva cotinine samples. We used a cut-off of 12 ng/ml to 
discriminate active smokers from non-smokers and correctly classified 97.6% of daily 
smokers. This cut-off was based on prior literature, and there is no “gold standard” level. 
Therefore, it is likely that some exposure misclassification occurred. Nevertheless, we used 
  49 
the saliva cotinine levels more as a confirmatory marker of what we observed in self-reported 
data, and the effect we observed could be an underestimation of the true association. 
In study V exposure to indicators of mold or dampness were also assessed by questionnaires, 
and some exposure misclassification is expected. In a nested case-control study, a home visit 
was conducted for 540 participants where an inspector assessed the presence of mold or 
dampness when the child was between one and two years of age. The correlation between 
parental reported and inspector noted signs of mold or dampness was somewhat low.
12
 The 
home visit was conducted in the first winter season (October–March) following the child’s 
recruitment into a case-control study, and mold or dampness in the home may have changed 
from the time the parent completed the questionnaire. Additionally, parents with allergic 
disease more frequently reported indicators of mold or dampness than parents without 
allergic disease, which could contribute to differential exposure misclassification. However, 
in study V we found that risk estimates were elevated both in children with and without 
parental allergic disease.
115
  
In epidemiological research how you choose to define your outcome is critical to avoiding 
misclassification. A too inclusive definition often includes those that really do not have the 
disease whereas a too stringent definition may exclude those with a more mild form of the 
disease. Therefore, finding an ideal definition can be challenging. This brings up the concept 
of sensitivity and specificity. The sensitivity of an outcome measurement is the probability 
that a subject who truly has the outcome is classified as such, and specificity is the probability 
that a subject not having the outcome will be classified as such.
159
  
Defining asthma is difficult, and there are no definitive diagnostic criteria or gold standard. 
What makes defining asthma even more challenging is the dynamic nature of the disease, 
with many forms and phenotypes. We used the same definition for asthma in studies I, II, and 
V which was stricter than the definition used in study III. The definition of asthma in all 
studies was based on a combination of reported symptoms, asthma medication in the last 12 
months, or doctor diagnosed asthma. Study III’s definition was agreed upon by a panel of 
experts in the MeDALL consortium and was chosen partly to accommodate different 
questions from the various cohorts and to facilitate harmonization of data.
164
 We observed 
minor regional differences in asthma prevalence which may reflect differing diagnostic 
criteria, as doctor diagnosed asthma was one of three criteria used to define asthma. The 
somewhat lower prevalence of asthma in the German cohorts (GINIplus, LISAplus, and 
MAS) might be explained by different diagnostic conventions between countries.
165
 The 
definition of asthma used in BAMSE was modified based on the ISAAC questionnaires 
which have been validated and are found to be accurate.
5
  
Defining IgE sensitization was based on IgE antibodies in blood, and is not subject to 
reporting bias. IgE levels in blood correlate well with skin-prick tests (SPT) and specific IgE 
antibodies measured by the CAP-RAST test.
166
 The decision to use 0.35 kUA/l was based on 
the literature and is widely used as a cut-off. Symptoms of allergic disease and IgE 
sensitization are correlated; however it is important to remember that they are not 
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synonymous. In other words, a subject can have a high IgE antibody levels but not present 
with any clinical symptoms and vice versa.   
Lung function was assessed by dynamic spirometry and impulse oscillometry (IOS) 
according to the ATS/ERS guidelines by well trained and experienced staff. These outcome 
measures are likely only to be affected by random error, and any misclassification is likely to 
be non-differential and would lead to a dilution of any true association.  
Misclassification of outcome could occur if mothers who quit smoking during early 
pregnancy may be more aware of respiratory symptoms in their offspring. These mothers 
may more readily seek healthcare or report symptoms differently than mothers who continue 
to smoke. Such reporting could potentially lead to an overestimation of the association. 
However, the reverse could also occur. Mothers who continue to smoke both during 
pregnancy and infancy may be less likely to report symptoms and seek healthcare less 
frequently than non-smoking mothers.
167 168
 Such reporting would lead to an underestimation 
of the true association.  
5.2.3 Confounding 
In observational studies one can never be entirely certain if the observed association is not 
due to uncontrolled or residual confounding. Confounding occurs when a factor (exposure, 
intervention, treatment, etc.) outside the studied exposure and outcome is related to both the 
exposure and the outcome.
158
 In other words, a confounding factor must fulfil three criteria: 
1) must be a risk factor for disease, 2) must be associated with the exposure under study, and 
3) must not be affected by the exposure or the disease.
159
 A commonly drawn directed acyclic 
graph (DAG) to illustrate this concept is below (Figure 21). For example, socioeconomic 
status could confound the association between maternal smoking during pregnancy and 
asthma because socioeconomic status is associated with both maternal smoking during 
pregnancy and asthma.
169 170
 Therefore we adjusted for socioeconomic status in studies I, II, 
and III. Maternal smoking during pregnancy is associated with low birthweight and may be 
considered a potential mediator of the association between maternal smoking during 
pregnancy and allergic outcomes.
171
 In studies I, II, III, and IV we explored the effect of 
birthweight but found no significant modifying effects. 
 
 
 
 
  
Figure 21. Example of a DAG. Where A represents exposure, Y the outcome, U is a 
confounder, and X is a mediator between A and Y. 
U 
A X Y 
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In the design process one must collect information on all potential confounding factors, 
which can later be used in the analysis phase and controlled for. In the BAMSE birth cohort 
and in the other cohorts included in study III, extensive questionnaires gather information on 
known and potential confounders. Additionally, repeated follow-up questionnaires continued 
to gather such information. 
The selection and control of confounders can be done in various ways. The selected 
confounders for studies I-V are presented in section 3.4. In general we selected covariates 
based on a priori knowledge as well as testing the influence of potential confounders on the 
effect estimate. The most common way to control for confounding is to include it in a 
multivariate model.  
A residual confounding factor that could influence the associations we found in the studies 
included in this thesis is paternal smoking during pregnancy. There are studies that suggest an 
association between paternal smoking during pregnancy and childhood asthma.
172
 We did not 
collect this information at baseline but this was asked at the 12 year follow-up. If paternal 
smoking during pregnancy is associated with allergic diseases, we likely underestimated 
effect of fetal exposure to tobacco smoke during pregnancy.   
Another source of confounding could be related to how we defined socioeconomic status 
(SES). Tobacco smoking is related to health outcomes as well as socioeconomic status. In 
studies I, II, IV, and V we defined socioeconomic status according to the Nordic standard 
occupational classification and Swedish socioeconomic classification and was based on 
parental occupation.
173
 There is the potential that this did not capture true socioeconomic 
status and that residual confounding remained. To address this, in sensitivity analyses we 
checked if mean income in the neighborhood affected our results but the effects were 
negligable.
161
  
5.2.4 Random error 
Random error, as the name implies, occurs by chance and largely affects the precision of risk 
estimates. Precision of an estimate is the lack or random error. The single most effective way 
to reduce random error and increase precision is to increase sample size. The width of 95% 
confidence intervals is one way of visualizing your precision; wide intervals indicate low 
precision and narrow ones suggests high precision.  
5.2.5 External validity – generalizability  
Generalizability refers to the ability to make inferences as they pertain to participants within 
your study population and generalize them to individuals outside the study population.
159
 To 
do this one must consider how the source population was selected. In BAMSE, 75% of 
eligible children born in Stockholm were included, and the only difference was seen in 
smoking rates. Thus it is reasonable to believe our sample was representative, and 
generalizable to Sweden, although not representative regarding tobacco smoke exposure.
134
 
Moreover, because BAMSE and the other cohorts included in study III (GINIplus and 
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LISAplus) were population-based and had high follow-up rates it is reasonable to assume that 
results can be generalized to the pediatric populations in high and middle income countries. 
There is also no obvious reason why tobacco smoke exposure or mold or dampness exposure 
would affect European children in different ways than other children around the world. If the 
underlying biological mechanisms are true there is no explanation why our findings would 
not be relevant for other populations. Due to the lower participation rate of smoking parents 
at recruitment (BAMSE), the impact of tobacco smoke exposure in the general population 
could possibly be slightly higher. High risk cohorts, such as MAS and PIAMA, may hamper 
generalizability as they are less comparable to the general population.   
5.2.6 Weighing the evidence – causality 
When drawing conclusions in epidemiological research and establishing causality 
consideration should be given to the following criteria adapted from Bradford Hill
174
:  
Strength of the association – stronger associations are more likely to be causal. 
Evidence of dose-response relationship – do higher doses of exposure have stronger 
effects on the outcome? 
Biological plausibility – is there evidence from both human and animal studies?  
Temporality – exposure should occur prior to disease onset. 
Specificity – is the association observed specific to a certain disease or particular 
individuals? In the case of smoking this criteria is less important because smoking is 
associated with multiple health outcomes.  
Consistency – how consistent is the evidence across studies? One study alone cannot 
establish causality but can contribute to the evidence base.  
Experiment – do experimental or intervention studies provide evidence of a causal 
relationship? 
Analogy – are analogous exposures also causally associated with disease?  
For example, we can ask the question, is tobacco smoking during pregnancy causally 
associated with asthma? Using the Bradford Hill criteria to assess the causality between 
maternal smoking during pregnancy and asthma our results achieve nearly all requirements. 
Specifically, we observed consistently elevated risk estimates, does-response associations, 
biological plausibility suggested by previous research, experimental studies using animal 
models support this association, consistency across other studies, and analogous associations 
are observed with other environmental exposures such as traffic related air pollution. Taken 
together this supports the hypothesis that maternal smoking during pregnancy is causally 
associated with asthma. One must keep always keep in mind that a single epidemiological 
study can never constitute full proof of causality.  
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5.3 MAIN FINDINGS AND GENERAL DISCUSSION 
5.3.1 Maternal smoking during pregnancy in relation to allergic disease and 
lung function 
Taken together we found that maternal smoking during pregnancy was associated with 
increased risk of asthma up to adolescence, and especially for early-transient asthma. We also 
found evidence for persistent asthma up to adolescence in participants exposed to high doses 
of maternal smoking during pregnancy. Additionally, we observed that highly exposed 
individuals during pregnancy were also at risk of persistent rhinoconjunctivitis. On the other 
hand, we found no association between maternal smoking during pregnancy and allergic 
sensitization or asthma with concomitant sensitization (i.e. allergic asthma). Exposure to 
maternal smoking during pregnancy was also associated with lower FEV1/FVC ratios and 
increased airway resistance at age 16 years, and suggests that exposure during pregnancy may 
have persistent effects on lung function up to adolescence. These measures also indicate early 
signs of airflow obstruction.  
Our finding of an association between maternal smoking during pregnancy and asthma 
development in early childhood is consistent with earlier studies.
42 65 67 175
 However, less is 
known about the risk of asthma as children reach adolescence, and the varying phenotypes 
related to onset and progression. In our studies we observed an increased risk of asthma up to 
adolescence which has been reported in other birth cohort studies.
175 176
 Earlier studies have 
also indicated that it is likely maternal smoking during pregnancy, and more importantly 
exposure during the first trimester that influences asthma development in children up to 
preschool age.
42
 It remains challenging to distinguish the effects of maternal smoking during 
pregnancy from adolescent smoking because many mothers that smoke during pregnancy 
continue to do so following delivery.
37
 Nevertheless, Neuman et al. effectively showed that 
maternal smoking during early pregnancy alone appears to increases the risk of wheeze in 
early childhood, a finding that is in line with our results.
42
 To our knowledge, study III was 
the first to study the onset, progression, and persistence of asthma up to adolescence. We 
found evidence of increased risk of persistent asthma among participants exposed to high 
doses of maternal smoking during pregnancy.    
Study IV is one of few prospective studies that assessed exposure to maternal smoking during 
pregnancy and concurrently accounted for exposure to adolescent smoking in relation to lung 
function in adolescents. Our finding for decreased FEV1/FVC ratios in children exposed to 
maternal smoking during pregnancy corroborates some prior studies
176-178
, whereas other 
studies have found declines in FEV1 or FVC which was not observed in our study.
179 180
 Our 
results confirm and extend those from the Isle of Wight cohort which also found reduced 
FEV1/FVC ratios among adolescents (mean age 18 years) exposed to maternal smoking 
during pregnancy.
177
 Additionally, in a cohort of 519 participants, Guerra et al. observed an 
early accelerated decline in FEV1/FVC ratios in 26 year olds, but only in subjects exposed to 
both adolescent smoking and maternal smoking during pregnancy.
103
 We also observed 
significant increases in peripheral airway resistance in adolescents exposed to maternal 
smoking during pregnancy. This is supported by previous studies which found reduced forced 
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expiratory flow at 25% to 75% of FVC (FEF25-75) which is suggestive of airflow in small 
airways.
177 180
 
Maternal smoking during pregnancy can impact a developing fetus in numerous ways. 
Compounds such as carbon monoxide, nicotine, cyanide, and sulfide are all known to cross 
the placental barrier.
181
 Fetal lung organogenesis begins in the fourth week of pregnancy and 
by the second trimester the majority of the conductive airways and terminal bronchioles are 
formed.
182
 Nicotine, the main constituent of tobacco smoke freely passes the placental barrier, 
and is linked with altered lung and alveolar architecture that can influence lung function.
39 183 
184
 Carbon monoxide, another byproduct of cigarette smoking, diminishes blood flow and the 
delivery of oxygen and nutrients to the fetus, which in turn can lead to intra-uterine growth 
retardation and impair the development of the respiratory system.
181
 Maternal smoking during 
pregnancy is also associated with DNA methylation in offspring and particularly in genes 
associated with asthma.
35
 Therefore, the association we find for both asthma and altered lung 
function among participants exposed to maternal smoking during pregnancy could be partly 
explained by these mechanisms. Collectively, this suggests that maternal smoking during 
pregnancy acts on the developing lung to influence the development of asthma and impact 
lung function up to adolescence.  
Although outside the scope of this work, we did observed suggestive evidence that paternal 
smoking during pregnancy may influence the development of asthma up to adolescence. This 
association has also been observed in other cohort studies in Europe and Canada among 
children up to seven years.
40 157
   
5.3.2 SHS during infancy in relation to allergic disease 
SHS exposure during infancy, without prior exposure during pregnancy, was associated with 
increased risk of food allergen sensitization at four years, with similar risk estimates at ages 
eight, and 16 years. Significant dose-response associations with an increasing number of 
cigarettes smoked was also seen. When we combined symptoms of asthma, rhinitis, and 
eczema with sensitization we found that SHS exposure during infancy increased the risk of 
eczema with sensitization. In line with this, we observed a somewhat increased risk of 
eczema among children exposed to SHS during infancy, which has been corroborated by 
others.
16 77 185
 SHS exposure during infancy was also associated with an overall risk of rhinitis 
up to adolescence with significant dose-response effects, and SHS exposure during infancy 
was mainly linked with rhinitis without sensitization. However, the risk estimates were 
highest in preschool age children and were less apparent as children became older.  
The literature is mixed when it comes to the association between exposure to tobacco smoke 
and sensitization. We observed an association between SHS during infancy and sensitization 
to food allergens which is in agreement with some studies in preschool age children
85 86
 but 
not all.
186 187
 Some studies have only reported increased risk of any sensitization among those 
with parental history of allergy,
78
 whereas others have found higher total IgE concentrations, 
but have not been able to identify specific types of allergens.
188
 Furthermore, some studies 
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have not distinguished between maternal smoking during pregnancy and SHS exposure 
postpartum. In study II we found no association between maternal smoking during pregnancy 
and sensitization, which is consistent with another birth cohort study based in Australia.
176
 
Given the various methodologies it is difficult to draw strong conclusions. 
The mechanisms behind exposure to SHS during infancy and sensitization to food allergens 
are not fully understood and are likely multifactorial. Some literature suggests that exposure 
to maternal smoking during pregnancy could preclude sensitization, presumably through an 
immunosuppressive effect, and that exposure postpartum influences the risk of allergic 
senstization.
33 189 190
 On the other hand exposure to SHS during infancy could induce 
inflammation of mucosal surfaces and increase antigen penetration leading to sensitization.
191
 
Another proposed mechanism, the dual allergen exposure hypothesis, suggests that exposure 
through the skin leads to sensitization, while exposure to allergens through consumption leads 
to tolerance – a process that may be facilitated by SHS expousre.192 Moreover, SHS exposure 
on the skin may impact sensitization due to damage to the proteins, lipids, and skin barrier 
allowing the passage of allergens through the skin.
193 194
 This mechanism could also explain 
our findings of an increased risk or eczema in subjects exposed to parental smoking during 
infancy.  
We observed increased risk of asthma up to adolescence in subjects exposed to SHS during 
infancy, and has been reported by others.
65 68
 However, as described earlier, disentangling the 
effects from maternal smoking during pregnancy from SHS exposure during infancy is 
challenging due to the high correlation between these exposures. Nevertheless, it seems 
plausible that exposure during infancy also confers increased risk of asthma, even though the 
majority of risk seems to be from exposure during pregnancy.     
The observed association between SHS during infancy and rhinitis up to adolescence is 
similar to other studies, but not all.
73 77 195 196
 The association we observed tended to subside 
as children reached adolescence, which could explain why other studies up to adolescence did 
not find an association between SHS exposure and rhinitis.
73 197
 Nevertheless, SHS exposure 
could influence the development of rhinitis through a combination of nasal irritation or 
obstruction as well as impairment in mucociliary clearance.
198
  
5.3.3 SHS throughout childhood in relation to allergic disease 
We consistently observed no significant associations between exposure to SHS during 
childhood or adolescence and asthma, rhinitis, rhinoconjunctivitis, or eczema. One possible 
explanation is that the perinatal period is a critical time window of development, and children 
are particularly sensitive to environmental exposures during this period. Analogous 
associations have been reported for traffic related air pollution as well as farming 
environments; in that early life exposure plays a crucial role for outcomes in later life.
14 199
 
During preschool ages children spend the majority of time in close vicinity of their parents 
and therefore more highly exposed during this vulnerable period. Parents may also try to 
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actively avoid exposing their children to SHS; for example 94% of parents in BAMSE 
reported smoking outdoors (on the balcony), near a window, or under the kitchen fan.
71
  
In studies I, II, and III, we adjusted our results for “exposure throughout childhood and 
adolescence” but this only slightly attenuated our results. The PIAMA cohort also found no 
association between SHS exposure and asthma from ages 4 to 17 years.
76
 Nevertheless, some 
cross-sectional studies have found associations between SHS exposure during childhood with 
asthma and respiratory symptoms in school age.
52 200
 A major limitation of these studies is the 
inability to adequately account for exposure during pregnancy, as this information is prone to 
recall bias. Moreover, exposure to SHS later in childhood is not always independent of 
symptoms of the child, since some parents may quit smoking if their child is diagnosed with 
asthma.
201
  
5.3.4 Adolescent smoking and lung function 
In study IV we observed a suggestive association between adolescent smoking and lower 
FEV1/FVC ratios and increased peripheral airway resistance, independent of maternal 
smoking during pregnancy. Our findings of lower FEV1/FVC ratios among adolescent 
smokers were corroborated when we used saliva cotinine concentrations to discriminate 
smokers from nonsmokers. Taken together, this suggests that even after a short duration of 
smoking, signs of airflow obstruction in adolescents were already apparent.  
To our knowledge study IV is the only study to assess lung function in adolescence using two 
methods to measure lung function and a biomarker of nicotine uptake. We observed lower 
FEV1/FVC ratios among adolescent smokers which is in agreement with previous studies in 
adolescence
202 203
, but not all.
100 103
 It was challenging to distinguish the effects of maternal 
smoking during pregnancy from adolescent smoking because 20% (n = 58) of adolescent 
smokers were also exposed to maternal smoking during pregnancy. Nevertheless, when we 
controlled for maternal smoking during pregnancy, risk estimates for adolescent smoking 
remained elevated. Although risk estimates were no longer statistically significant, we believe 
this is likely due to insufficient power. Additionally, we used saliva cotinine concentrations in 
relation to lung function to provide a unique assessment of actual nicotine uptake and to 
confirm our finding of reduced FEV1/FVC ratios in smoking participants.  
Alveolarization continues into early adulthood, and humans do not reach peak lung volume 
until their early 20’s.202 It is probable that smoking in adolescence negatively impacts lung 
growth, and exposure to tobacco smoke in adults is causally associated with COPD, lung 
cancer, pneumonia, and chronic bronchitis.
204 205
 Smoker’s lungs show diffuse changes 
affecting the airway lining, epithelium, and bronchiole arcitecture.
206
 Although a one to two 
percent-unit decline in FEV1/FVC ratio may be small, impairments in lung function at an 
early age can limit the peak development in adulthood, and potentially set a course for COPD 
or other lung related disease in later life.  
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5.3.5 Mold and dampness in relation to allergic disease  
We found that exposure to any indicator of mold or dampness during infancy was associated 
with an increased risk of asthma up to adolescence, particularly persistent asthma. Our results 
also suggested that exposure to any indicator of mold or dampness was associated with non-
allergic asthma (asthma without IgE sensitization). We observed increased risk of rhinitis, but 
only among children exposed to mold odor and visible mold. Similar to asthma, we found 
that exposure increased the risk of non-allergic rhinitis. 
Studying the association between reported indicators of mold or dampness in a home can be 
challenging, as reporting is subjective, and studies use various methodologies to assess 
exposure. Even so, there is consistent epidemiological evidence indicating that factors related 
to dampness in a home are associated with asthma risk in children.
15 109 110
 The literature is 
less consistent for rhinitis, but there is evidence suggesting that exposure to mold or 
dampness is associated with increased rhinitis risk.
15 126 130
 Exposure to compounds related to 
molds such as β-1-3-glucans, microbial volatile organic compounds, extracellular 
polysaccharides, and mycotoxins can cause recurrent irritation and immune activation of the 
respiratory tract.
109 110 114
 After repeated exposure and extended inflammation, inflammatory-
related diseases can develop, such as asthma and rhinitis. Because we found increased risks 
of non-allergic asthma and rhinitis, it is plausible that the relevant compounds cause a more 
irritative effect rather than allergic inflammatory changes in the respiratory tract.
115
 
As mentioned earlier, it is challenging to subjectively identify and quantify mold and 
dampness exposure. Parental reported mold or dampness is subject to bias, as described in 
section 5.2.2. Although home inspection is a more objective and standardized way of 
assessing household mold or dampness, this is often costly, time consuming, and not practical 
in large populations. Furthermore, intra-inspector variation is not uncommon, and mold or 
dampness damage within walls can be overlooked.
207 208
 Nevertheless, studies utilizing 
inspector reported indicators of mold and dampness have reported similar results to ours.
209
 
Finally, these indicators of mold or dampness themselves do not cause an effect, but are 
markers of chemical and microbial processes in a home that influences health, and to date the 
compounds responsible for asthma and rhinitis are not fully elucidated.   
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6 CONCLUSIONS  
Taken together, our findings indicate that the perinatal period may be critical for the influence 
of tobacco smoke exposure as well as mold or dampness on allergy related diseases and/or 
lung function. From the separate studies it may be concluded that:  
 Maternal smoking during pregnancy appears to increase the risk of asthma during 
childhood and adolescence, especially early-transient asthma. Heavy exposure during 
pregnancy (≥10 cigarettes/day) may be associated with persistent asthma and 
persistent rhinoconjunctivitis. Furthermore, exposure to maternal smoking during 
pregnancy seemed to be associated with early signs of airway obstruction expressed 
as lower FEV1/FVC ratios and increased airway resistance at age 16 years. 
 
 SHS exposure during infancy may be associated with rhinitis up to age 16 years, with 
highest risks in children under 12 years of age, as well as with IgE sensitization to 
food allergens up to age 16 years, and eczema combined with sensitization.  
 
 Adolescent smoking tended to be associated with reduced FEV1/FVC ratios and 
increased peripheral airway resistance at age 16 years, suggesting development of 
airflow obstruction from only a short duration of smoking. 
 
 Exposure to indicators of mold or dampness in the home during infancy appears to 
increase the risk of asthma, specifically persistent asthma up to age 16 years, as well 
as of rhinitis up to age 16 years, particularly in subjects without IgE sensitization. 
Identification of the causal agents remains elusive and further studies are needed.   
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7 FUTURE DIRECTIONS AND PUBLIC HEALTH 
IMPLICATIONS 
Tobacco smoke exposure is causally linked to several detrimental health effects and there are 
no safe levels of maternal smoking during pregnancy or SHS. Despite continued health 
campaigns, tobacco smoking remains a pervasive problem, and the use of new tobacco 
products such as e-cigarettes and smokeless tobacco has increased.
210 211
 Many smokers try 
their first cigarette in early adolescence and establish habits that can persist into adulthood.
202
 
From a public health perspective the prevention or cessation of smoking should be 
paramount. Various smoking cessation campaigns have been met with mixed results 
worldwide. Banning smoking in public places such as bus stops, restaurants, and by building 
entrances is suggested to improve the health of non-smokers and reduce smoking rates, but 
has not been shown in all studies and remains controversial.
48 212
 Services such as counseling, 
support, and nicotine replacement therapy should continue to be provided. In high and middle 
income countries most of the population are aware of the negative health effects from 
smoking. Making access to smoking more difficult may be an effective strategy in reducing 
smoking rates. 
Findings from this thesis can be used by health professionals to motivate mothers to quit 
smoking before conceiving, and for parents to abstain from smoking around their children to 
potentially prevent allergic disease, sensitization, and lung function impairments. Continued 
research is needed to assess the impact of e-cigarettes and other nicotine delivery systems. 
Additionally, the follow-up of individuals into adulthood to evaluate the persistence, new-
onset, severity of symptoms, and exacerbations related to tobacco smoking is needed from 
long-term cohort studies, such as BAMSE. Intervention studies are also necessary to identify 
the most cost-effective ways to curb smoking rates and prevent adolescents from taking up 
smoking. Studies are also necessary to evaluate who is at risk to take up smoking and types of 
individuals that have difficulty quitting to inform future preventive strategies.  
Epidemiologic research with qualitative and quantitative assessment of dampness and 
dampness-related agents must be conducted, as the evidence on the development of incident 
asthma as well as rhinitis remains inconclusive. Future research should focus on identifying 
the causal agents through cell or animal models, and the use of personal monitoring devices. 
Although epidemiological studies consistently observe associations between home dampness 
and respiratory outcomes the causal agents and biological mechanisms are not completely 
understood. This makes public health policy or intervention programs challenging to 
implement. Moreover, the development and use of validated metrics are necessary and to 
identify health-relevant thresholds of agents generated by indoor mold or dampness.  
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8 SVENSK SAMMANFATTNING 
Astma och andra allergiska sjukdomar är de vanligaste kroniska sjukdomarna i västvärlden 
och förekommer hos cirka 30 procent av befolkningen. Den ökade förekomsten av dessa 
sjukdomar har lett till studier av hur miljöfaktorer och livsstil kan påverka risken för 
allergisjukdomar. Det övergripande målet med denna avhandling var att undersöka 
sambandet mellan faktorer i inomhusmiljön – som exponering för miljötobaksrök och fukt 
eller mögel i bostaden – och utveckling av allergisjukdomar från födseln till 16 års ålder. 
Studierna har genomförts med hjälp av data från en populationsbaserad födelsekohort 
(BAMSE) där 4089 barn följts från födseln upp till 16 års ålder. I en av delstudierna användes 
data från BAMSE tillsammans med data från fyra andra europeiska födelsekohorter, där totalt 
10860 barn inkluderades. 
Våra studier visade att barn vars mammor rökte under graviditeten hade en ökad risk för 
astma upp i tonåren, där riskökningen var särskilt uttalad i förskoleåldern. Barn till mammor 
som rökt 10 cigaretter per dag eller mer hade även en ökad risk för kvarstående astmasymtom 
och rinit (hösnuva) upp till 16 års ålder. Barn vars mammor rökte under graviditeten hade 
även en nedsatt lungfunktion (vilket visade sig genom lägre FEV1/FVC mätt med spirometri) 
samt en ökning i luftvägsmotståndet i de små luftvägarna (mätt med impulsoscillometri).  
Exponering för miljötobaksrök (definierat som att mamma eller pappa rökte) under 
spädbarnstiden var associerat med en ökad risk för astma, rinit och eksem upp till 16 års 
ålder. Våra resultat tyder dock på att riskökningen för astma till största delen kan förklaras av 
mammans rökning under graviditeten. Resultaten visar även att exponering för 
miljötobaksrök under spädbarnstiden var associerat med en ökad förekomst av 
allergiantikroppar mot födoämnen hos barn som inte exponerats för mammas rökning under 
graviditeten. Exponering för miljötobaksrök senare under barndomen var inte kopplat till 
någon ökad risk för nyinsjuknande i astma eller rinit i tonåren.  
Jämfört med icke-rökare, hade studiedeltagare som rökte vid 16 års ålder (ibland eller 
dagligen) en nedsatt lungfunktion, även efter att vi tagit hänsyn till om de exponerats för 
mammas rökning under graviditeten. Vi mätte även förekomsten av kotinin i saliv hos 
studiedeltagarna vid 16 års ålder för att kunna skilja rökare från icke-rökare. De som hade 
förhöjda nivåer av kotinin i saliven (som tyder på egen rökning) hade en nedsatt lungfunktion 
jämfört med dem med lägre nivåer. 
Exponering för fukt och mögel i bostaden under spädbarnstiden var kopplat till en ökad risk 
för astma upp till 16 års ålder, liksom en ökad risk för kvarstående astmasymtom. Våra 
resultat tyder även på att förekomst av mögellukt eller synligt mögel i bostaden under 
spädbarnstiden kan öka risken för rinit upp till 16 års ålder. Däremot såg vi inget samband 
mellan förekomst av fukt och mögel i bostaden och nivåer av allergiantikroppar i blodet.  
Sammanfattningsvis visar resultaten i denna avhandling att faktorer i inomhusmiljön, som 
exponering för miljötobaksrök och fukt eller mögel i bostaden tidigt i livet, kan påverka 
utvecklingen av allergisjukdomar upp tonåren. Barn vars mammor rökte under graviditeten 
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hade även en nedsatt lungfunktion vid 16 års ålder. Vi såg även tendenser till 
lungfunktionsnedsättning hos rökande tonåringar. Resultaten från studierna kan ligga till 
grund för preventiva hälsoinsatser i befolkningen. 
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